Top

Scott E. Evans, MD, FCCP, ATSF

Department of Pulmonary Medicine, Division of Internal Medicine

Present Title & Affiliation

Primary Appointment

Endowed Chair, Rebecca Meyer Brown and Joseph Mellinger Brown Chair in Basic Science Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston

Department Chair ad interim, Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

Regular Faculty Member, Department of Program in Molecular & Translational Biology, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Regular Faculty Member, Department of Program in Immunology, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Adjunct Professor, School of Medicine, Tecnologico de Monterrey, Monterrey

Research Interests

The entirety of my professional effort, both laboratory and clinical, is focused on the mechanisms that prevent humans from universally succumbing to the microbial pathogens they inhale or aspirate every day. In particular, I am interested in how non-HIV immunocompromised patients respond to the presence of respiratory pathogens. My goal is to exploit these native mechanisms to provide more comprehensive protection during episodes of peak vulnerability, such as when cancer patients receive chemotherapy. My laboratory is currently engaged full-time in mechanistic studies intended to unravel the means by which our recently described phenomenon of inducible resistance protects against pneumonia. Our available data indicate that this protective response occurs via antimicrobial product generation from treated respiratory epithelial cells, rather than through the typical leukocyte effectors of the innate immune system. My long term objective is to develop a research program focused on discovery and manipulation of epithelium-derived antimicrobial mediators that can ultimately be translated for clinical benefit.

Education & Training

Degree-Granting Education

1999	University of Texas Medical School, San Antonio, Texas, US, MD
1994	University of Texas, Austin, Texas, US, Plan II Honors Program, BA

Postgraduate Training

2008-2013	Physician-Scientist Training Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
2004-2005	Administrative (Chief) Fellow, Pulmonary Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota
2002-2004	Clinician-Investigator Research Training Program, Mayo Graduate School of Medicine, Rochester, Minnesota
2002-2005	Clinical Fellowship, Pulmonary & Critical Care Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota
1999-2002	Clinical Internship and Residency, Internal Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota

Board Certifications

2006	Critical Care Medicine, American Board of Internal Medicine
2005	Pulmonary Medicine, American Board of Internal Medicine
2002	Internal Medicine, American Board of Internal Medicine

Experience & Service

Academic Appointments

Associate Professor, Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019

Graduate Faculty, Texas A&M Health Science Center School of Graduate Studies, College Station, TX, 2010 - 2015

Adjunct Faculty, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, 2006 - 2015

Assistant Professor, Department of Critical Care Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2009

Assistant Professor, Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2013

Assistant Professor, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, 2005

Instructor, Mayo Clinic College of Medicine, Rochester, MN, 2001 - 2005

Administrative Appointments/Responsibilities

Department Chair ad interim, Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present

Director of Basic and Translational Research, Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2021

Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2006 - 2009

Medical Director, Department of Pulmonary Function Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2010

Other Appointments/Responsibilities

Ad hoc Member, Pharmacy Compounding Advisory Committee, US Food and Drug Administration, 2022 - Present

Member, Clinical Steering Committee, National Forum to Secure America’s Supply Chain for Essential Medicines, US Department of Health and Human Services, 2021 - Present

Faculty, Center for Perioperative Medicine, UTHealth McGovern Medical School, Houston, TX, 2021 - Present

Member, Pulmonary-Allergy Drugs Advisory Committee, US Food and Drug Administration, 2019 - Present

Ad hoc Member, Antimicrobial Drugs Advisory Committee, US Food and Drug Administration, 2018 - Present

Faculty, MD Anderson Medical Mycology Research Center, Houston, TX, 2018 - Present

Ad hoc Member, Pulmonary-Allergy Drugs Advisory Committee, US Food and Drug Administration, 2014 - 2019

Institutional Committee Activities

Member, Division of Intenal Medicine Promotion and Tenure Subcommittee, 2024 - Present

Member, Tenure Renewal Taskforce, 2023 - 2024

Member, Academic Leadership Team, 2022 - Present

Member, Hospital Medicine Chair Advisory Committee, 2022 - 2024

Member, Community of Chairs Budget Subcommittee, 2022 - Present

Member, The University of Texas MD Anderson Cancer Center, Jack and Beverly Randall Excellence in Cancer Treatment Award Review Committee, 2022

Member, Ambulatory COVID-19 Core Leadership Team (A-CCLT), 2022 - Present

Roundtable Huddle Member, Research Leadership Team, 2022 - Present

Member, CCSG Research Programs/Community Outreach & Engagement (RP COE) Collaborative Workgroup, 2022 - 2024

Chair, Promotion and Tenure Committee, 2022 - 2023

Co-Chair, Infectious Diseases, Infection Control and Employee Health Chair Search Committee, 2021 - 2023

Vice-Chair, Promotion and Tenure Committee, 2021 - 2022

Member, Biochemistry and Cell Biology Program Examination Committee, 2020 - 2022

Member, CCSG Research Animal Support Facility Program Income Advisory Committee, 2020 - Present

Member, Promotion and Tenure Committee, 2019 - 2021

Member, Program in Immunology Admissions Subcommittee, 2018 - 2021

Member, Multidisciplinary Research Program Committee, 2018 - 2021

Member, Program in Immunology Steering Committee, 2016 - 2018

Member, Physician-Scientist Program Advisory Committee, 2014 - Present

Member, Physician-Scientist Task Force, 2014 - 2016

Member, Institutional Infection Control Committee, 2008 - Present

Member, Planning Committee, Conference on Bronchoscopic Techniques in Interventional Pulmonary Oncology, 2007 - Present

Member, Pneumonia Working Group, 2006 - Present

Member, Division of Internal Medicine Biomarker Development Subcommittee, 2006 - 2007

Member, Division of Internal Medicine Research Committee, 2005 - 2008

Member, Division of Pulmonary & Critical Care Medicine Education Committee, 2004 - 2005

Fellow Representative, Division of Pulmonary & Critical Care Medicine Hospital Practice Committee, 2004 - 2005

Member, Division of Pulmonary & Critical Care Medicine Research Committee, 2002 - 2005

Member, Admissions Committee, 1998 - 1999

Member, Medical Dean's Class Presidents Committee, 1996 - 1999

Honors & Awards

2022	Elected Member, American Society for Clinical Investigation
2019	Cyrus Scholar Award, Cyrus Family Foundation
2019	Fellow, American Thoracic Society
2016	Pulmonary Infection and Tuberculosis Assembly Mid-Career Peer Recognition Award, American Thoracic Society
2014	Cyrus Scholar Award, Cyrus Family Foundation
2014	Presidential Recognition for Faculty Excellence, The University of Texas MD Anderson Cancer Center
2013	Distinguished Paper Award, The University of Texas MD Anderson Division of Internal Medicine
2013	NIH Director's New Innovator Award, NIH Office of the Director
2010	Cyrus Scholar Award, Cyrus Family Foundation
2008	Charles E. Culpeper Scholarship in Medical Science, Partnership for Cures/Culpeper Foundation
2008	Fellow, American College of Chest Physicians
2008	Physician-Scientist Award, The University of Texas MD Anderson Cancer Center
2008	Best Abstract, The University of Texas MD Anderson Cancer Center Division of Internal Medicine Research Retreat
2007	NIH Loan Repayment Program Award, Clinical Research
2007	Best Poster: Basic Science-Diagnostics, The University of Texas MD Anderson Cancer Center Division of Internal Medicine Retreat
2007	Best Poster: Clinical-Prevention, The University of Texas MD Anderson Cancer Center Division of Internal Medicine Retreat
2007	Career Development Award, University of Texas Centers for Clinical and Translational Science
2005	Travel Grant, American Thoracic Society
2004	Burgher Family Endowed Pulmonary Fellowship Award
2003	Second Place, National CHEST Challenge, American College of Chest Physicians
2003	Trainee Travel Award, Experimental Biology, Federation of American Societies for Experimental Biology
2003	Young Investigator Award, ACCP Chest Foundation
2003	Scholar Award, GlaxoSmithKline
2002	Graduation Rank #1, Mayo Internal Medicine Residency Program
2002	Outstanding Achievement Award, Mayo Internal Medicine Residency Program
2002	Travel Award, Combined Annual Meeting, Central Society for Clinical Research
2002	Young Investigator Endowed Fellowship, Hartz Foundation
2002 - 2003	Trainee Travel Award, Clinical Research, American Federation for Medical Research
2001	Travel Award, 4th Annual International LAM Research Conference, NHLBI/LAM Foundation
1999	Holt Leadership Award, University of Texas Medical School
1998	Alpha Omega Alpha Honor Medical Society
1997	National Achievement Award, American Medical Association/GlaxoWellcome
1997 - 1999	University of Texas Medical School Alumni Scholarship (first three-time recipient)
1996	Certificate of Excellence for Outstanding Service, Texas State Senate
1993	Order of Omega Academic Honor Society
1992	Theta Award for Academic Excellence, University of Texas at Austin
1990	National Merit/Interlogic Trace Scholar
1990	Terry Foundation Scholar

Professional Memberships

American Board of Internal Medicine

2022 - 2023

American Society for Clinical Investigation

2022 - Present

European Respiratory Society

2019 - Present

American Society for Microbiology

2018 - Present

Texas Medical Association

2005 - Present

Society of Critical Care Medicine

2002 - Present

American Thoracic Society

2002 - Present

American College of Chest Physicians

2002 - Present

American Federation of Medical Research

2001 - 2004

Zumbro Valley Medical society

1999 - 2005

Minnesota Medical Association

1999 - 2005

Alpha Omega Alpha Honor Medical Society

1998 - Present

Association of American Medical Colleges

1996 - Present

American College of Physicians-American Society of Internal Medicine

1995 - Present

American Medical Association

1995 - Present

Selected Publications

Peer-Reviewed Articles

Ryerson CJ, Jennerich AL, Nici L, Raghu G, Ghazipura M, Aaron SD, Cristea AI, Dela Cruz C, Drummond MB, Ehsan Z, Evans SE, Feller-Kopman D, Hayes D Jr, Iyer NP, Jenkins AR, Holland AE, Jacobs SS, Krishnan JA, Macrea M, Oren E, Owens RL, Rochwerg B, Strange C, Wilson KC. Clinical Practice Guidelines: Quality, Breadth, and Currency. Ann Am Thorac Soc, 2025. e-Pub 2025. PMID: 40523263.
Pantaleon Garcia J, Wurster S, Albert ND, Bharadwaj U, Bhoda K, Kulkarni VK, Ntita M, Rodriguez Carstens P, Burch-Eapen M, Covarrubias Lopez D, Foncerrada Lizaola J, Larsen KE, Matula LM, Moghaddam SJ, Wang Y, Kontoyiannis DP, Evans SE. Immunotherapy with nebulized pattern recognition receptor agonists restores severe immune paralysis and improves outcomes in mice with influenza-associated pulmonary aspergillosis. mBio 16(5):e0406124, 2025. e-Pub 2025. PMID: 40197039.
Mir M, Soto F, Gomez PAA, Arroyo RDR, Suresh A, Su A, Gan Q, Stewart J, Adachi R, Balachandran DD, Bashoura L, Casal RF, Dickey BF, Eapen GA, Evans SE, Grosu H, Jimenez CA, Lin J, Ost DE, Sabath BF, Shannon VR, Naing A, Gao J, Wu J, Suresh K, Faiz SA, Altan M, Sheshadri A. Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitis. Front Med (Lausanne) 12:1582714, 2025. e-Pub 2025. PMID: 40529125.
Epelbaum O, Marinelli T, Haydour QS, Pennington KM, Evans SE, Carmona EM, Husain S, Knox KS, Jarrett BJ, Azoulay E, Hope WW, Meyer-Zilla A, Murad MH, Limper AH, Hage CA. Treatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients. An Of fi cial American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med, 2024. e-Pub 2024. PMID: 39556361.
Wang Y, Kulkarni VV, Pantaleon Garcia J, Longmire MK, Lethier M, Cusack S, Evans SE. The RNA receptor RIG-I binding synthetic oligodeoxynucleotide promotes pneumonia survival. JCI Insight 9(21), 2024. e-Pub 2024. PMID: 39352770.
Matsuo, T, Wurster, ST, Jiang, Y, Tarrand, JJ, Evans, S, Kontoyiannis, DP. Determinant of 30-Day Mortality of Pulmonary Legionellosis. Open Forum Infectious Diseases 11(9), 2024. e-Pub 2024. PMID: 39319087.
Auld SC, Sheshadri A, Alexander-Brett J, Aschner Y, Barczak AK, Basil MC, Cohen KA, Dela Cruz C, McGroder C, Restrepo MI, Ridge KM, Schnapp LM, Traber K, Wunderink RG, Zhang D, Ziady A, Attia EF, Carter J, Chalmers JD, Crothers K, Feldman C, Jones BE, Kaminski N, Keane J, Lewinsohn D, Metersky M, Mizgerd JP, Morris A, Ramirez J, Samarasinghe AE, Staitieh BS, Stek C, Sun J, Evans SE. Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc 21(9):1219-1237, 2024. e-Pub 2024. PMID: 39051991.
Matsuo T, Wurster S, Jiang Y, Tarrand J, Evans SE, Kontoyiannis DP. Determinant of 30-Day Mortality of Pulmonary Legionellosis: Do Coinfections Matter?. Open Forum Infect Dis 11(9):ofae529, 2024. e-Pub 2024. PMID: 39319087.
Shanley, M, Daher, M, Dou, J, Li, S, Basar, R, Rafei, H, Dede, M, Gumin, J, Pantaleόn Garcίa, J, Nunez Cortes, AK, He, S, Jones, C, Acharya, S, Fowlkes, NW, Xiong, D, Singh, S, Shaim, H, Hicks, SC, Liu, B, Jain, A, Zaman, MF, Miao, Q, Li, YE, Uprety, N, Liu, E, Muniz-Feliciano, L, Deyter, GM, Mohanty, V, Zhang, P, Evans, S, Shpall, EJ, Lang Jr, FF, Chen, K, Rezvani, K. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer cell 42(8):1450-1466.e11, 2024. e-Pub 2024. PMID: 39137729.
Shojaee S, Pannu J, Yarmus L, Fantin A, MacRosty C, Bassett R Jr, Debiane L, DePew ZS, Faiz SA, Jimenez CA, Avasarala SK, Vakil E, DeMaio A, Bashoura L, Keshava K, Ferguson T, Adachi R, Eapen GA, Ost DE, Bashour S, Khan A, Shannon V, Sheshadri A, Casal RF, Evans SE, Pew K, Castaldo N, Balachandran DD, Patruno V, Lentz R, Pai C, Maldonado F, Roller L, Ma J, Zaveri J, Los J, Vaquero L, Ordonez E, Yermakhanova G, Akulian J, Burks C, Almario RR, Sauve M, Pettee J, Noor LZ, Arain MH, Grosu HB. Gravity- vs Wall Suction-Driven Large-Volume Thoracentesis: A Randomized Controlled Study. Chest 166(6):1573-1582, 2024. e-Pub 2024. PMID: 39029784.
Sheshadri A, Rajaram R, Baugh A, Castro M, Correa AM, Soto F, Daniel CR, Li L, Evans SE, Dickey BF, Vaporciyan AA, Ost DE. Association of Preoperative Lung Function with Complications after Lobectomy Using Race-Neutral and Race-Specific Normative Equations. Ann Am Thorac Soc 21(1):38-46, 2024. e-Pub 2024. PMID: 37796618.
Johnson AN, Dickinson J, Nelson A, Gaurav R, Kudrna K, Evans SE, Janike K, Wyatt TA, Poole JA. Effect of epithelial-specific MyD88 signaling pathway on airway inflammatory response to organic dust exposure. J Immunotoxicol 20(1):2148782, 2023. e-Pub 2023. PMID: 36538286.
Wang Y, Kulkarni VV, Pantaleon Garcia J, Leiva-Juarez MM, Goldblatt DL, Gulraiz F, Vila Ellis L, Chen J, Longmire MK, Donepudi SR, Lorenzi PL, Wang H, Wong LJ, Tuvim MJ, Evans SE. Antimicrobial mitochondrial reactive oxygen species induction by lung epithelial immunometabolic modulation. PLoS Pathog 19(9):e1011138, 2023. e-Pub 2023. PMID: 37695784.
Noh S, Bertini C, Mira-Avendano I, Kaous M, Patel B, Faiz SA, Shannon VR, Balachandran DD, Bashoura L, Adachi R, Evans SE, Dickey B, Wu C, Shroff GS, Manzano JG, Granwehr B, Holloway S, Dickson K, Mohammed A, Muthu M, Song H, Chung C, Wu J, Lee L, Jiang Y, Khawaja F, Sheshadri A. Interstitial lung abnormalities after hospitalization for COVID-19 in patients with cancer: A prospective cohort study. Cancer Med 12(17):17753-17765, 2023. e-Pub 2023. PMID: 37592894.
Kulkarni VV, Wang Y, Pantaleon Garcia J, Evans SE. Redox-Dependent Activation of Lung Epithelial STAT3 Is Required for Inducible Protection against Bacterial Pneumonia. Am J Respir Cell Mol Biol 68(6):679-688, 2023. e-Pub 2023. PMID: 36826841.
Wurster S, Pantaleón García J, Albert ND, Jiang Y, Bhoda K, Kulkarni VV, Wang Y, Walsh TJ, Evans S, Kontoyiannis DP. Development of a corticosteroid-immunosuppressed mouse model to study the pathogenesis and therapy of influenza-associated pulmonary aspergillosis. J Infect Dis 227(7):901-906, 2023. e-Pub 2023. PMID: 36611269.
Cheng GS, Crothers K, Aliberti S, Bergeron A, Boeckh M, Chien JW, Cilloniz C, Cohen K, Dean N, Dela Cruz CS, Dickson RP, Greninger AL, Hage CA, Hohl TM, Holland SM, Jones BE, Keane J, Metersky M, Miller R, Puel A, Ramirez J, Restrepo MI, Sheshadri A, Staitieh B, Tarrand J, Winthrop KL, Wunderink RG, Evans SE. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc 20(3):341-353, 2023. e-Pub 2023. PMID: 36856712.
Chau, KM, Dominic, A, Davis, EL, Kotla, S, Berrios, ET, Fahim, A, Arunesh, A, Li, S, Zhao, D, Chen, K, Davis, AR, Nguyen, MT, Wang, Y, Evans, S, Wang, G, Cooke, J, Abe, J, Huston, DP, Le, NT. TNIK regulation of interferon signaling and endothelial cell response to virus infection. Frontiers in Cardiovascular Medicine 10, 2023. e-Pub 2023. PMID: 38264262.
Velasco WV, Khosravi N, Castro-Pando S, Torres-Garza N, Grimaldo MT, Krishna A, Clowers MJ, Umer M, Tariq Amir S, Del Bosque D, Daliri S, De La Garza MM, Ramos-Castaneda M, Evans SE, Moghaddam SJ. Toll-like receptors 2, 4, and 9 modulate promoting effect of COPD-like airway inflammation on K-ras-driven lung cancer through activation of the MyD88/NF-kB pathway in the airway epithelium. Front Immunol 14:1118721, 2023. e-Pub 2023. PMID: 37283745.
Chau KM, Dominic A, Davis EL, Kotla S, Berrios ET, Fahim A, Arunesh A, Li S, Zhao D, Chen K, Davis AR, Nguyen MTH, Wang Y, Evans SE, Wang G, Cooke JP, Abe JI, Huston DP, Le NT. TNIK regulation of interferon signaling and endothelial cell response to virus infection. Front Cardiovasc Med 10:1213428, 2023. e-Pub 2023. PMID: 38264262.
Pantaleón García J, Dickson RP, Evans SE. Minimizing caging effects in murine lung microbiome studies. Am J Physiol Lung Cell Mol Physiol 323(2):L219-L220, 2022. e-Pub 2022. PMID: 35944140.
Goldblatt DL, Valverde Ha G, Wali S, Kulkarni VV, Longmire MK, Jaramillo AM, Chittuluru RP, Fouts A, Purresh TF, Martinez-Moczygemba M, Lei JT, Huston DP, Tuvim MJ, Dickey BF, Evans SE. Epithelial immunomodulation by aerosolized Toll-like aeceptor agonists attenuates allergic responsiveness in mice. Eur J Pharmacol, 2022. e-Pub 2022.
Wang Y, Velatooru LR, Vu HT, Gulraiz F, Wang Y, Thomas TN, Masaki I, Kolta S, le NT, Evans SE, Abe J. Influenza A virus infection increases MAGI1 expression in endothelial cells and itsdepletion inhibits virus replication through increased expression of MX1. Frontiers in Cardiology, 2022. e-Pub 2022. PMID: 36082118.
Losier A, Harding WC, Dela Cruz CS, Evans S, Ruminjo JK, Thomson C. Summary for Clinicians: Clinical Practice Guideline for the Use of Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. Ann Am Thorac Soc 19(7):1081-1083, 2022. e-Pub 2022. PMID: 35353672.
Pantaleón García J, Kulkarni VV, Reese TC, Wali S, Wase SJ, Zhang J, Singh R, Caetano MS, Kadara H, Moghaddam SJ, Johnson FM, Wang J, Wang Y, Evans SE. OBIF: an Omics-based interaction framework to reveal molecular drivers of synergy. NAR Genom Bioinform 4(2):lqac028, 2022. e-Pub 2022. PMID: 35387383.
Cheng GS, Evans SE. The paradox of immunosuppressants and COVID-19. Eur Respir J 59(4), 2022. e-Pub 2022. PMID: 34795039.
Goldblatt DL, Valverde Ha G, Wali S, Kulkarni VV, Longmire MK, Jaramillo AM, Chittuluru RP, Fouts A, Martinez-Moczygemba M, Lei JT, Huston DP, Tuvim MJ, Dickey BF, Evans SE. Epithelial immunomodulation by aerosolized Toll-like receptor agonists prevents allergic inflammation in airway mucosa in mice. Front Pharmacol 13:833380, 2022. e-Pub 2022. PMID: 36105216.
Wang Y, Abe JI, Chau KM, Wang Y, Vu HT, Reddy Velatooru L, Gulraiz F, Imanishi M, Samanthapudi VSK, Nguyen MTH, Ko KA, Lee LL, Thomas TN, Olmsted-Davis EA, Kotla S, Fujiwara K, Cooke JP, Zhao D, Evans SE, Le NT. MAGI1 inhibits interferon signaling to promote influenza A infection. Front Cardiovasc Med 9:791143, 2022. e-Pub 2022. PMID: 36082118.
Pantaleón García J, Hinkle KJ, Falkowski NR, Evans SE, Dickson RP. Selective Modulation of the Pulmonary Innate Immune Response Does not Change Lung Microbiota in Healthy Mice. Am J Respir Crit Care Med 204(6):734-736, 2021. e-Pub 2021. PMID: 34153197.
Smith AM, Harper N, Meunier JA, Branum AP, Jimenez F, Pandranki L, Carrillo A, Dela Cruz CS, Restrepo MI, Maselli DJ, Rather CG, Heisser AH, Ramirez DA, He W, Clark RA, Andrews CP, Evans SE, Pugh JA, Zhang N, Lee GC, Moreira AG, Segal LN, Ramirez RM, Jacobs RL, Manoharan MS, Okulicz JF, Ahuja SK. Repetitive aeroallergen challenges elucidate maladaptive epithelial and inflammatory traits that underpin allergic airway diseases. J Allergy Clin Immunol 148(2):533-549, 2021. e-Pub 2021. PMID: 33493557.
Czopik A, Yuan X, Evans SE, Eltzschig HK. Targeting the Hypoxia-Adenosine Link for Controlling Excessive Inflammation. Anesthesiology 135(1):15-17, 2021. e-Pub 2021. PMID: 34046661.
Dela Cruz CS, Evans SE, Restrepo MI, Dean N, Torres A, Amara-Elori I, Awasthi S, Caler E, Cao B, Chalmers JD, Chastre J, Cohen TS, Cohen AH, Crothers K, Di YP, Egan ME, Feldman C, Gautam S, Halstead ES, Herold S, Jones BE, Luna C, Niederman MS, Mendez R, Menendez R, Mizgerd JP, Nusrat R, Ramirez J, Shindo Y, Waterer G, Yeligar SM, Wunderink RG. Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc 18(7):1087-1097, 2021. e-Pub 2021. PMID: 34242148.
Epelbaum O, Carmona EM, Evans SE, Hage CA, Jarrett B, Knox KS, Limper AH, Pennington KM. Antifungal Prophylaxis for Adult Recipients of Veno-Venous Extracorporeal Membrane Oxygenation: A Cautionary Stance During the COVID-19 Pandemic. ASAIO J 67(6):611-613, 2021. e-Pub 2021. PMID: 33769344.
Cilloniz C, Simonds A, Hansen K, Alouch J, Zar H, Nakanishi Y, Levine S, Cohen M, Dela Cruz C, Evans SE, Sanguinetti M, Vila J, Díez Manglano J, Ferrer R, Criado L, Polo García J, Correcher Z, Rodriguez-Hurtado D, Terrazas C, Muñoz-Almagro C, Garcia-Vidal C, Aoun Z, Amirav I. Pulse oximetry is an essential tool that saves lives: a call for standardisation. Eur Respir J 57(6), 2021. e-Pub 2021. PMID: 34088755.
Evans SE, Jennerich AL, Azar MM, Cao B, Crothers K, Dickson RP, Herold S, Jain S, Madhavan A, Metersky ML, Myers LC, Oren E, Restrepo MI, Semret M, Sheshadri A, Wunderink RG, Dela Cruz CS. Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 203(9):1070-1087, 2021. e-Pub 2021. PMID: 33929301.
Tsoi KM, Lowe M, Tsuda Y, Lex JR, Fujiwara T, Almeer G, Gregory J, Stevenson J, Evans SE, Botchu R, Jeys LM. How Are Indeterminate Pulmonary Nodules at Diagnosis Associated with Survival in Patients with High-Grade Osteosarcoma?. Clin Orthop Relat Res 479(2):298-308, 2021. e-Pub 2021. PMID: 32956141.
Yuan X, Ferrari D, Mills T, Wang Y, Czopik A, Doursout MF, Evans SE, Idzko M, Eltzschig HK. Purinergic Signaling and Inflammation. Front Immunol 12:699069, 2021. e-Pub 2021. PMID: 34093597.
Wali S, Flores JR, Jaramillo AM, Goldblatt DL, Pantaleón García J, Tuvim MJ, Dickey BF, Evans SE. Immune Modulation to Improve Survival of Viral Pneumonia in Mice. Am J Respir Cell Mol Biol 63(6):758-766, 2020. e-Pub 2020. PMID: 32853024.
Ramirez JA, Musher DM, Evans SE, Dela Cruz C, Crothers KA, Hage CA, Aliberti S, Anzueto A, Arancibia F, Arnold F, Azoulay E, Blasi F, Bordon J, Burdette S, Cao B, Cavallazzi R, Chalmers J, Charles P, Chastre J, Claessens YE, Dean N, Duval X, Fartoukh M, Feldman C, File T, Froes F, Furmanek S, Gnoni M, Lopardo G, Luna C, Maruyama T, Menendez R, Metersky M, Mildvan D, Mortensen E, Niederman MS, Pletz M, Rello J, Restrepo MI, Shindo Y, Torres A, Waterer G, Webb B, Welte T, Witzenrath M, Wunderink R. Management of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. Chest 158(5):1896-1911, 2020. e-Pub 2020. PMID: 32561442.
Evans SE, Tseng CK, Scott BL, Höök AM, Dickey BF. Inducible Epithelial Resistance Against Coronavirus Pneumonia in Mice. Am J Respir Cell Mol Biol 63(4):540-541, 2020. e-Pub 2020. PMID: 32706609.
Dawood W, Evans SE, Grosu H. Mediastinal lymphadenitis due to Nocardia infection. J Bronchology Interv Pulmonol 27(3):e48-e51, 2020. e-Pub 2020. PMID: 32569081.
Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17?. Nat Rev Immunol 20(6):345-346, 2020. e-Pub 2020. PMID: 32358580.
Wunderink RG, Srinivasan A, Barie PS, Chastre J, Dela Cruz CS, Douglas IS, Ecklund M, Evans SE, Evans SR, Gerlach AT, Hicks LA, Howell M, Hutchinson ML, Hyzy RC, Kane-Gill SL, Lease ED, Metersky ML, Munro N, Niederman MS, Restrepo MI, Sessler CN, Simpson SQ, Swoboda SM, Guillamet CV, Waterer GW, Weiss CH. Antibiotic Stewardship in the Intensive Care Unit: An Official American Thoracic Society Workshop Report in Collaboration with the AACN, CHEST, CDC, and SCCM. Ann Am Thorac Soc 17(5):531-540, 2020. e-Pub 2020. PMID: 32356696.
Goldblatt DL, Flores JR, Valverde Ha G, Jaramillo AM, Tkachman S, Kirkpatrick CT, Wali S, Hernandez B, Ost DE, Scott BL, Chen J, Evans SE, Tuvim MJ, Dickey BF. Inducible epithelial resistance against acute Sendai virus infection prevents chronic asthma-like lung disease in mice. Br J Pharmacol 177(10):2256-2273, 2020. e-Pub 2020. PMID: 31968123.
Covés-Datson EM, King SR, Legendre M, Gupta A, Chan SM, Gitlin E, Kulkarni VV, Pantaleón García J, Smee DF, Lipka E, Evans SE, Tarbet EB, Ono A, Markovitz DM. A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo. Proc Natl Acad Sci U S A 117(4):2122-2132, 2020. e-Pub 2020. PMID: 31932446.
Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct immunophenotypes of T cells in bronchoalveolar lavage fluid from leukemia patients with immune checkpoint inhibitors-related pulmonary complications. Front Immunol 11:590494, 2020. e-Pub 2020. PMID: 33552049.
Hage CA, Carmona EM, Evans SE, Limper AH, Ruminjo J, Thomson CC. Summary for Clinicians: Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. Ann Am Thorac Soc 16(12):1473-1477, 2019. e-Pub 2019. PMID: 31526275.
Vichaya EG, Gross PS, Estrada DJ, Cole SW, Grossberg AJ, Evans SE, Tuvim MJ, Dickey BF, Dantzer R. Lipocalin-2 is dispensable in inflammation-induced sickness and depression-like behavior. Psychopharmacology (Berl) 236(10):2975-2982, 2019. e-Pub 2019. PMID: 30806746.
Hage CA, Carmona EM, Epelbaum O, Evans SE, Gabe LM, Haydour Q, Knox KS, Kolls JK, Murad MH, Wengenack NL, Limper AH. Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 200(5):535-550, 2019. e-Pub 2019. PMID: 31469325.
Haydour Q, Hage CA, Carmona EM, Epelbaum O, Evans SE, Gabe LM, Knox KS, Kolls JK, Wengenack NL, Prokop LJ, Limper AH, Murad MH. Diagnosis of Fungal Infections: A Systematic Review and Meta-Analysis Supporting ATS Clinical Practice Guideline. Ann Am Thorac Soc 16(9):1179-1188, 2019. e-Pub 2019. PMID: 31219341.
Sheshadri A, Karimipour M, Vakil E, Bashoura L, Godoy M, Arain MH, Evans SE, Dickey BF, Ost DE, Chemaly RF, Faiz SA. Refinement of estimates of mortality risk using the Radiologic Severity Index in hematologic malignancy patients with respiratory syncytial virus infection. Transpl Infect Dis 21(4):e13105, 2019. e-Pub 2019. PMID: 31081570.
Abe JI, Ko KA, Kotla S, Wang Y, Paez-Mayorga J, Shin IJ, Imanishi M, Vu HT, Tao Y, Leiva-Juarez MM, Thomas TN, Medina JL, Won JH, Fujii Y, Giancursio CJ, McBeath E, Shin JH, Guzman L, Abe RJ, Taunton J, Mochizuki N, Faubion W, Cooke JP, Fujiwara K, Evans SE, Le NT. MAGI1 as a link between endothelial activation and ER stress drives atherosclerosis. JCI Insight 4(7), 2019. e-Pub 2019. PMID: 30944250.
Ware HH, Kulkarni VV, Wang Y, Pantaleón García J, Leiva Juarez M, Kirkpatrick CT, Wali S, Syed S, Kontoyiannis AD, Sikkema WKA, Tour JM, Evans SE. Inducible lung epithelial resistance requires multisource reactive oxygen species generation to protect against bacterial infections. PLoS One 14(2):e0208216, 2019. e-Pub 2019. PMID: 30794556.
Sheshadri A, Godoy M, Erasmus JJ, Gruschkus S, Hasan A, Evans SE, Barreda-Garcia J, Chemaly RF, Dickey B, Ost D. Progression of the Radiologic Severity Index is associated with increased mortality and healthcare resource utilisation in acute leukaemia patients with pneumonia. BMJ Open Respir Res 6(1):e000471, 2019. e-Pub 2019. PMID: 31921429.
Caetano MS, Hassane M, Van HT, Bugarin E, Cumpian AM, McDowell CL, Cavazos CG, Zhang H, Deng S, Diao L, Wang J, Evans SE, Behrens C, Wistuba II, Fuqua SAW, Lin H, Stabile LP, Watowich SS, Kadara H, Moghaddam SJ. Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nat Commun 9(1):4589, 2018. e-Pub 2018. PMID: 30389925.
Fernández-Cruz A, Magira E, Heo ST, Evans S, Tarrand J, Kontoyiannis DP. Bronchoalveolar lavage fluid cytology in culture-documented invasive pulmonary aspergillosis in patients with hematologic diseases: analysis of 67 episodes. J Clin Microbiol 56(10), 2018. e-Pub 2018. PMID: 30021823.
Dela Cruz CS, Wunderink RG, Christiani DC, Cormier SA, Crothers K, Doerschuk CM, Evans SE, Goldstein DR, Khatri P, Kobzik L, Kolls JK, Levy BD, Metersky ML, Niederman MS, Nusrat R, Orihuela CJ, Peyrani P, Prince AS, Ramírez JA, Ridge KM, Sethi S, Suratt BT, Sznajder JI, Tsalik EL, Walkey AJ, Yende S, Aggarwal NR, Caler EV, Mizgerd JP. Future Research Directions in Pneumonia: NHLBI Working Group Report. Am J Respir Crit Care Med 198(2):256-263, 2018. e-Pub 2018. PMID: 29546996.
Khosravi N, Caetano MS, Cumpian AM, Unver N, De la Garza Ramos C, Noble O, Daliri S, Hernandez BJ, Gutierrez BA, Evans SE, Hanash S, Alekseev AM, Yang Y, Chang SH, Nurieva R, Kadara H, Chen J, Ostrin EJ, Moghaddam SJ. IL-22 promotes K-ras mutant lung cancer by induction of a pro-tumor immune response and protection of stemness properties. Cancer Immunol Res 6(7):788-797, 2018. e-Pub 2018. PMID: 29764837.
Kirkpatrick CT, Wang Y, Leiva Juarez MM, Shivshankar P, Pantaleón García J, Plumer AK, Kulkarni VV, Ware HH, Gulraiz F, Chavez Cavasos MA, Martinez Zayes G, Wali S, Rice AP, Liu H, Tour JM, Sikkema WKA, Cruz Solbes AS, Youker KA, Tuvim MJ, Dickey BF, Evans SE. Inducible lung epithelial resistance requires multisource reactive oxygen species generation to protect against viral infections. MBio 9(3), 2018. e-Pub 2018. PMID: 29764948.
Leiva-Juarez MM, Kirkpatrick CT, Gilbert BE, Scott B, Tuvim MJ, Dickey BF, Evans SE, Markesich D. Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir. Eur J Pharmacol 818:191-197, 2018. e-Pub 2018. PMID: 29066417.
Leiva-Juárez MM, Kolls JK, Evans SE. Lung epithelial cells: therapeutically inducible effectors of antimicrobial defense. Mucosal Immunol 11(1):21-34, 2018. e-Pub 2018. PMID: 28812547.
Sheshadri A, Shah DP, Godoy M, Erasmus JJ, Song J, Li L, Evans SE, Chemaly RF, Dickey BF, Ost DE. Progression of the radiologic severity index predicts mortality in patients with parainfluenza virus-associated lower respiratory infections. PLoS One 13(5):e0197418, 2018. e-Pub 2018. PMID: 29771962.
Leiva-Juárez MM, Ware HH, Kulkarni VV, Zweidler-McKay PA, Tuvim MJ, Evans SE. Inducible epithelial resistance protects mice against leukemia-associated pneumonia. Blood 128(7):982-92, 2016. e-Pub 2016. PMID: 27317793.
Faiz SA, Bashoura L, Kodali L, Hessel AC, Evans SE, Balachandran DD. Sleep disordered breathing as a delayed complication of iatrogenic vocal cord trauma. Sleep Med 22:1-3, 2016. e-Pub 2016. PMID: 27544828.
Yang J, Hernandez BJ, Martinez Alanis D, Narvaez del Pilar O, Vila-Ellis L, Akiyama H, Evans SE, Ostrin EJ, Chen J. The development and plasticity of alveolar type 1 cells. Development 143(1):54-65, 2016. e-Pub 2016. PMID: 26586225.
Gonzalez CE, Johnson TN, Evans S, Kidin LM, George S, Haq S, DeJesus AY, Walters R, Rolston K. Assessing compliance with established pneumonia core measures at a comprehensive cancer center. J Healthc Qual 37(4):232-44, 2015. e-Pub 2015. PMID: 24629128.
Han XY, Ihegword A, Evans SE, Zhang J, Li L, Cao H, Tarrand JJ, El-Kweifi O. Microbiological and clinical studies of legionellosis in 33 patients with cancer. J Clin Microbiol 53(7):2180-7, 2015. e-Pub 2015. PMID: 25926494.
Xia X, Mai J, Xu R, Perez JE, Guevara ML, Shen Q, Mu C, Tung HY, Corry DB, Evans SE, Liu X, Ferrari M, Zhang Z, Li XC, Wang RF, Shen H. Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. Cell Rep 11(6):957-66, 2015. e-Pub 2015. PMID: 25937283.
Gonzalez C, Johnson T, Rolston K, Merriman K, Warneke C, Evans S. Predicting pneumonia mortality using CURB-65, PSI, and patient characteristics in patients presenting to the emergency department of a comprehensive cancer center. Cancer Med 3(4):962-70, 2014. e-Pub 2014. PMID: 24802800.
Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, Alexander SN, Bellinghausen LK, Song AS, Petrova YM, Tuvim MJ, Adachi R, Romo I, Bordt AS, Bowden MG, Sisson JH, Woodruff PG, Thornton DJ, Rousseau K, De la Garza MM, Moghaddam SJ, Karmouty-Quintana H, Blackburn MR, Drouin SM, Davis CW, Terrell KA, Grubb BR, O'Neal WK, Flores SC, Cota-Gomez A, Lozupone CA, Donnelly JM, Watson AM, Hennessy CE, Keith RC, Yang IV, Barthel L, Henson PM, Janssen WJ, Schwartz DA, Boucher RC, Dickey BF, Evans CM. Muc5b is required for airway defence. Nature 505(7483):412-6, 2014. e-Pub 2014. PMID: 24317696.
Cleaver JO, You D, Michaud DR, Pruneda FA, Juarez MM, Zhang J, Weill PM, Adachi R, Gong L, Moghaddam SJ, Poynter ME, Tuvim MJ, Evans SE. Lung epithelial cells are essential effectors of inducible resistance to pneumonia. Mucosal Immunol 7(1):78-88, 2014. e-Pub 2014. PMID: 23632328.
Alfaro VY, Goldblatt DL, Valverde GR, Munsell MF, Quinton LJ, Walker AK, Dantzer R, Varadhachary A, Scott BL, Evans SE, Tuvim MJ, Dickey BF. Safety, tolerability, and biomarkers of the treatment of mice with aerosolized toll-like receptor ligands. Front Pharmacol 5:8, 2014. e-Pub 2014. PMID: 24567720.
Garcia JB, Lei X, Wierda W, Cortes JE, Dickey BF, Evans SE, Ost DE. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc 10(5):432-40, 2013. e-Pub 2013. PMID: 23987587.
Tuvim MJ, Clement CG, Huang ES, Cote GJ, Evans SE, Lei X, Deftos LJ, Gagel RF, Dickey BF. Deletion of the gene encoding calcitonin and CGRPα does not affect the outcome of severe infection in mice. Am J Respir Cell Mol Biol 49(1):151-5, 2013. e-Pub 2013. PMID: 23526213.
Drake MG, Evans SE, Dickey BF, Fryer AD, Jacoby DB. TLR2/6 and TLR9 agonists suppress viral replication but not airway hyperreactivity in guinea pigs. Am J Respir Cell Mol Biol 48(6):790-6, 2013. e-Pub 2013. PMID: 23449736.
Evans SE, Kottom TJ, Pagano RE, Limper AH. Primary alveolar epithelial cell surface membrane microdomain function is required for Pneumocystis β-glucan-induced inflammatory responses. Innate Immun 18(5):709-16, 2012. e-Pub 2012. PMID: 22334619.
Tuvim MJ, Gilbert BE, Dickey BF, Evans SE. Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia (***Top 10% most cited papers for this journal***). PLoS One 7(1):e30596, 2012. e-Pub 2012. PMID: 22299046.
Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: A prospective 2-year study. Cancer 117(15):3424-33, 2011. e-Pub 2011. PMID: 21246537.
Evans SE, Tuvim MJ, Fox CJ, Sachdev N, Gibiansky L, Dickey BF. Inhaled innate immune ligands to prevent pneumonia. Br J Pharmacol 163(1):195-206, 2011. e-Pub 2011. PMID: 21250981.
Duggan JM, You D, Cleaver JO, Larson DT, Garza RJ, Guzmán Pruneda FA, Tuvim MJ, Zhang J, Dickey BF, Evans SE. Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice. J Immunol 186(10):5916-26, 2011. e-Pub 2011. PMID: 21482737.
Ochoa CE, Mirabolfathinejad SG, Ruiz VA, Evans SE, Gagea M, Evans CM, Dickey BF, Moghaddam SJ. Interleukin 6 but not T helper 2 cytokines promotes lung carcinogenesis. Cancer Prev Res (Phila) 4(1):51-64, 2011. e-Pub 2011. PMID: 21098042.
Evans SE, Leventakos K, Ben-Ami R, You D, Thakkar SG, Lewis RE, Kontoyiannis DP. Toll-deficient Drosophila are resistant to infection by Pneumocystis spp.: additional evidence of specificity to mammalian hosts. Virulence 1(6):523-525, 2010. e-Pub 2010. PMID: 21178507.
Evans SE, Tuvim MJ, Zhang J, Larson DT, Garcia CD, Martinez Pro S, Coombes KR, Dickey BF. Host lung gene expression patterns predict infectious etiology in a mouse model of pneumonia. Respir Res 11(1):101, 2010. e-Pub 2010. PMID: 20653947.
Evans SE, Scott BL, Clement CG, Larson DT, Kontoyiannis D, Lewis RE, Lasala PR, Pawlik J, Peterson JW, Chopra AK, Klimpel G, Bowden G, Höök M, Xu Y, Tuvim MJ, Dickey BF. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol 42(1):40-50, 2010. e-Pub 2010. PMID: 19329554.
Tuvim MJ, (Co-First Author) ES, Clement CG, Dickey BF, Gilbert BE. Augmented lung inflammation protects against influenza A pneumonia. PLoS One 4(1):e4176, 2009. e-Pub 2009. PMID: 19137067.
Clement CG, Tuvim MJ, Evans CM, Tuvin DM, Dickey BF, Evans SE. Allergic lung inflammation alters neither susceptibility to Streptococcus pneumoniae infection nor inducibility of innate resistance in mice. Respir Res 10(10):70, 2009. e-Pub 2009. PMID: 19635139.
Clement CG, (Co-First Author) ES, Evans CM, Hawke D, Kobayashi R, Reynolds PR, Moghaddam SJ, Scott BL, Melicoff E, Adachi R, Dickey BF, Tuvim MJ. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med 177(12):1322-30, 2008. e-Pub 2008. PMID: 18388354.
Evans SE, Hahn PY, McCann F, Kottom TJ, Pavlovic' ZV, Limper AH. Pneumocystis cell wall β-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-ĸB-dependent mechanisms. Am J Respir Cell Mol Biol 32(6):490-7, 2005. e-Pub 2005. PMID: 15746433.
Gilman G, Evans SE, Hansen WH, Barnes ME, Klarich KW. Evaluation of right pulmonary artery obstruction by echocardiography in a 32-year-old woman with suggested histoplasmosis. J Am Soc Echocardiogr 18(5):490-1, 2005. e-Pub 2005. PMID: 15891762.
Evans SE, Colby TV, Ryu JH, Limper AH. Transforming growth factor-β1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis. Chest 125(3):1063-70, 2004. e-Pub 2004. PMID: 15006970.
Hahn PY, (Co-First Author) ES, Kottom TJ, Standing JE, Pagano RE, Limper AH. Pneumocystis carinii cell wall β-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J Biol Chem 278(3):2043-50, 2003. e-Pub 2003. PMID: 12419803.
Limper AH, Lebron F, Evans SE, Hahn RY. Pneumocystis carinii: cell wall β-glucan-mediated pulmonary inflammation. J Eukaryot Microbiol 50 Suppl(SUPPL):646, 2003. e-Pub 2003. PMID: 14736200.
Wali S, Dickey BF, Evans SE. Targeting CD8+ T cell immunopathology in severe viral pneumonia. Am J Respir Cell Mol Biol.

Invited Articles

Sheshadri A, Evans SE. RSV Vaccination in the adult pulmonary patient. Chest 166(5):963-974, 2024. e-Pub 2024. PMID: 38885895.
Shivshankar P, Karmouty-Quintana H, Mills T, Doursout MF, Wang Y, Czopik AK, Evans SE, Eltzschig HK, Yuan X. SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. Inflammation 45(4):1430-1449, 2022. e-Pub 2022. PMID: 35320469.
Yuan X, Mills T, Doursout MF, Evans SE, Vidal Melo MF, Eltzschig HK. Alternative adenosine Receptor activation: The netrin-Adora2b link. Front Pharmacol 13:944994, 2022. e-Pub 2022. PMID: 35910389.
Johnston SL, Goldblatt DL, Evans SE, Tuvim MJ, Dickey BF. Airway epithelial innate immunity. Front Physiol 12:749077, 2021. e-Pub 2021. PMID: 34899381.
Young AY, Leiva Juarez MM, Evans SE. Fungal pneumonia in patients with hematologic malignancy and hematopoietic stem cell transplantation. Clin Chest Med 38(3):479-491, 2017. e-Pub 2017. PMID: 28797490.
Wong JL, Evans SE. Bacterial pneumonia in patients with cancer: novel risk factors and management. Clin Chest Med 38(2):263-277, 2017. e-Pub 2017. PMID: 28477638.
Vakil E, Evans SE. Viral pneumonia in patients with hematologic malignancy or hematopoietic stem cell transplantation. Clin Chest Med 38(1):97-111, 2017. e-Pub 2017. PMID: 28159165.
Evans SE, Ost DE. Pneumonia in the neutropenic cancer patient. Curr Opin Pulm Med 21(3):260-71, 2015. e-Pub 2015. PMID: 25784246.
Evans SE. ATS Virtual Symposium: Coping with Candida infections. Proc Am Thorac Soc 7(3):197-203, 2010. e-Pub 2010. PMID: 20463248.
Evans SE, Xu Y, Tuvim MJ, Dickey BF. Inducible innate resistance of lung epithelium to infection. Annu Rev Physiol 72:413-35, 2010. e-Pub 2010. PMID: 20148683.
Safdar A, Shelburne SA, Evans SE, Dickey BF. Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin Drug Saf 8(4):435-49, 2009. e-Pub 2009. PMID: 19538104.
Evans SE, McDonald FS, Scanlon PD. An approach to pulmonary function testing. Respiratory Review 2(6):40-44, 2006. e-Pub 2006.
Evans SE, Scanlon PD. Current practice in pulmonary function testing. Mayo Clin Proc 78(6):758-763, 2003. e-Pub 2003. PMID: 12934788.

Manuals, Teaching Aids, Other Teaching Publications

Evans SE, Nishimura RA. General Guidelines for Patient Care on the Cardiovascular Hospital Services, 2003.

Editorials

Cheng GS, Ramirez JA, Staitieh BS, Evans SE. Challenges of Managing Pulmonary Disease in the Immunocompromised Host. Clin Chest Med 46(1):xiii-xvii, 2025. PMID: 39890296.
Cilloniz C, Dela Cruz CS, Dy-Agra G, Pagcatipunan RS Jr. World Pneumonia Day 2024: Fighting Pneumonia and Antimicrobial Resistance. Am J Respir Crit Care Med 210(11):1283-1285, 2024. PMID: 39530671.
Pantaleon Garcia J, Evans SE. Omics-based profiles and biomarkers of respiratory infections: are we there yet?. Eur Respir J 63(3), 2024. PMID: 38453245.
Xia Z, Zhong W, Wu M, Evans SE. Editorial: The interplay between microbiota and allergen in shaping respiratory mucosa immunity: Role in development of asthma. Front Immunol 14:1131215, 2023. PMID: 36875065.

Abstracts

Wang Y, Kulkarni VV, Pantaleón García J, Longmire MK, Lethier M, Cusack S, Evans SE. RIG-I Is a Cytosolic Receptor of CPG Oligodeoxynucleotides That Can Be Manipulated to Protect Against Pneumonia. American Journal of Respiratory and Critical Care Medicine 207:A1224, 2023. e-Pub 2023.
Pantaleón García J, Wurster ST, Albert ND, Bhoda K, Wang Y, Kontoyiannis DP, Evans SE. Immunotherapy with Pam2+ODN improves morbidity and mortality against influenza-associated pulmonary aspergillosis in a corticosteroid-immunosuppressed murine model. American Journal of Respiratory and Critical Care Medicine 207:A3888, 2023. e-Pub 2023.
Ntita M, Longmire MK, Wang Y, Pantaleon-Garcia J, Kulkarni VV, Evans SE. Epithelial immunomodulation by aerosolized Toll-like agonists prevents allergic lung inflammation by reducing Th2 polarization. American Journal of Respiratory and Critical Care Medicine 207:A2546, 2023. e-Pub 2023.
Longmire MK, Pantaleón García J, Evans SE. Modeling inducible epithelial resistance against murine betacoronavirus. American Journal of Respiratory and Critical Care Medicine 207:A5591, 2023. e-Pub 2023.
Longmire MK, Bodnar J, Pantaleón García J, Wang Y, Evans SE. Interferon regulatory factor 3 is activated in lung epithelial cells following Pam2/ODN treatment. American Journal of Respiratory and Critical Care Medicine 207:A6759, 2023. e-Pub 2023.
Pantaleón García J, Bhoda K, Kulkarni VV, Wang Y, Evans SE. Pathogen-agnostic transcriptional responses are preserved in mouse and human lung epithelium during inducible resistance signaling against respiratory infections. American Journal of Respiratory and Critical Care Medicine 207:A5607, 2023. e-Pub 2023.
Kulkarni VV Wang Y, Pantaleón García J, Evans SE. Pam2-ODN induces protection against acute bacterial pneumonia by redox based activation of lung epithelial STAT3. American Journal of Respiratory and Critical Care Medicine 205:A1201, 2022. e-Pub 2022.
Longmire M, Bodnar JP, Pantaleón García J, Wang Y, Evans SE. Combined Toll-like receptor agonist treatment leads to activation of interferon regulatory factor 3 in lung epithelial cells in vitro. American Journal of Respiratory and Critical Care Medicine 205:A1217, 2022. e-Pub 2022.
Wang Y, Kulkarni VV, Pantaleón García J, Lethier M, Cusack S, Evans SE. RIG-I is a novel receptor for CpG oligodeoxynucleotides. American Journal of Respiratory and Critical Care Medicine 205:A1207, 2022. e-Pub 2022.
Pantaleon-Garcia J, Pacheco Hernandez LM, Kulkarni VV, Longmire M, Wang Y, Evans SE. Inducible resistance against viral pneumonia requires a lung epithelium-specific transcriptional interaction between RelA and c-Jun. American Journal of Respiratory and Critical Care Medicine 205:A1194, 2022. e-Pub 2022.
Kulkarni VV, Wang Y, Pantaleón García J, Evans SE. ROS mediated epithelial STAT3 activation Is required for Pam2/ODN induced resistance to pneumonia. American Journal of Respiratory and Critical Care Medicine 203:A3902, 2021. e-Pub 2021.
Longmire MK, Reese TC, Chavez MA, Wang Y, Evans SE. Toll-like receptor 9 Toll/interleukin-1R domain-mediated signaling is dispensable in inducible resistance to influenza A infection in human bronchial epithelial cells. American Journal of Respiratory and Critical Care Medicine 203:A3906, 2021. e-Pub 2021.
Goldblatt DL, Fouts A, Valverde-Ha G, Martinez-Moczygemba M, Huston D, Tuvim MJ, Dickey BF, Evans SE. Aerosolized Toll-like receptor agonists modulate type 2 allergic inflammation. American Journal of Respiratory and Critical Care Medicine 203:A1347, 2021. e-Pub 2021.
Pantaleon-Garcia J, Zhang J, Kulkarni VV, Wali S, Longmire MK, Wang J, Wang Y, Evans SE. Antiviral immunomodulatory signaling of inducible epithelial resistance recalibrates host response to coronavirus and influenza infection. American Journal of Respiratory and Critical Care Medicine 203:A3771, 2021. e-Pub 2021.
Wali S, Goldblatt DL, Pantaleón García J, Tuvim MJ, Dickey BF, Evans SE. Targeting CD8+ T Cell immunopathology to improve survival of viral pneumonia in mice. American Journal of Respiratory and Critical Care Medicine 203:A3896, 2021. e-Pub 2021.
Pantaleon-Garcia J, Kulkarni VV, Reese TC, Wase S, Wang Y, Evans SE. Transcriptional cooperation between RelA and Jun/Fos promotes differential NF-kB activity required for inducible epithelial resistance against viral pneumonia. American Journal of Respiratory and Critical Care Medicine 201:A1180, 2020. e-Pub 2020.
Goldblatt DL, Valverde Ha G, Fouts A, Wali S, Martinez-Moczygemba M, Huston DP, Tuvim MJ, Dickey BF, Evans SE. Aerosolized Toll-like receptor agonists suppress allergic inflammation. American Journal of Respiratory and Critical Care Medicine 201:A4271, 2020. e-Pub 2020.
Wali S, Flores Gonzalez JR, Goldblatt D, Tuvim MJ, Dickey BF, Evans SE. Inducible epithelial resistance inactivates Sendai virus and protects against CD8+ T Cell mediated immunopathology. American Journal of Respiratory and Critical Care Medicine 201:A1172, 2020. e-Pub 2020.
Johnson A, Dickinson JD, Nelson A, Evans SE, Dickey BF, Poole JA. Airway inflammatory response and Muc5ac mucus cell metaplasia following agricultural organic dust exposure Is dependent on epithelial-specific adaptor protein MyD88. American Journal of Respiratory and Critical Care Medicine 201:A1792, 2020. e-Pub 2020.
Kulkarni VV, Wang Y, Pantaleon-Garcia J, Wali S, Evans SE. Epithelial STAT 3 Is required for Pam2/ODN induced resistance to pneumonia. American Journal of Respiratory and Critical Care Medicine 201:A3981, 2020. e-Pub 2020.
Pantaleon-Garcia J, Kulkarni V, Wang Y, Evans SE. Synergistic gene and protein expression analyses reveal roles of NFkB and JUN in inducible epithelial resistance against infection. American Journal of Respiratory and Critical Care Medicine 199:A5597, 2019. e-Pub 2019.
Goldblatt DL, Valverde G, Tkachman S, Martinez-Mocygemba M, Huston DP, Tuvim MJ, Dickey BF, Evans SE. Aerosolized Toll-like receptor agonists suppress house dust mite allergic asthma. American Journal of Respiratory and Critical Care Medicine 199:A2893, 2019. e-Pub 2019.
Goldblatt DL, Gonzalez JF, Valverde G, Jaramillo AM, Tkachman S, Wali S, Hernandez B, Scott B, Chen J, Evans SE, Tuvim MJ, Dickey BF. Aerosolized Toll-Like Receptor Agonists Suppress Acute Sendai Virus Burden and Chronic Asthma-Like Lung Disease in Mice. American Journal of Respiratory and Critical Care Medicine 199:A1208, 2019. e-Pub 2019.
Wali S, Goldblatt D, Flores Gonzalez JR, Tuvim MJ, Dickey BF, Evans SE. Inducible epithelial resistance prevents CD8+T cell-dependent lethal immunopathology following respiratory viral infections. American Journal of Respiratory and Critical Care Medicine 199:A1202, 2019. e-Pub 2019.
Wang Y, Leiva-Juarez M, Kulkarni V, Pantaleon-Garcia, J, Wali S, Evans SE. Phosphorothiorate oligonucleotide stimulated mitochondrial reactive oxygen species mediate lung epithelial innate resistance to bacterial infection. American Journal of Respiratory and Critical Care Medicine 199:A1219, 2019. e-Pub 2019.
Wang Y, Kulkarni VV, Leiva-Juarez MM, Wali S, Gulraiz F, Chavez Cavazos M, Evans SE. Mechanisms of ODN-induced epithelial reactive oxygen species generation and its role in inducible resistance to influenza infection. American Journal of Respiratory and Critical Care Medicine 197:A5495, 2018. e-Pub 2018.
Wali S, Flores Gonzalez JR, Tuvim MJ, Dickey BF, Evans SE. Toll-like receptor signaling reveals differential gene expression profiles involved in prevention of virus-induced asthma. American Journal of Respiratory and Critical Care Medicine 197:A5493, 2018. e-Pub 2018.
Khosravi N, Torres-Garza N, Daliri S, De La Garza MM, Cumpian AM, Beltran E, Umer M, Del Bosque D, Akbani S, Evans SE, Moghaddam SJ. Toll like receptors mediated inflammatory signals mediate promotion of K-ras mutant lung cancer by chronic obstructive pulmonary disease. Cancer Research 77:2687, 2017. e-Pub 2017.
Leiva MM, Wang Y, Kulkarni VV, Batres S, Evans SE. Mitochondrial reactive oxygen species in lung epithelial cells are induced by oligodeoxynucleotides in a MyD88 and TRAF6-independent Manner. American Journal of Respiratory and Critical Care Medicine 195:A4044, 2017. e-Pub 2017.
Wali S, Wang Y, Leiva MM, Batres S, Kulkarni, VV, Goldblatt B, Flores J, Tuvim MJ, Evans SE. Protection against viral pneumonia following inhalation of synergistic TLR agonists is not mediated by induction of type I interferons. American Journal of Respiratory and Critical Care Medicine 195:A4924, 2017. e-Pub 2017.
Leiva MM, Wang Y, Kulkarni VV, Batres S, Wali S, Evans SE. Toll-like receptor-induced epithelial antiviral resistance affects the early influenza viral cycle with an associated upregulation in IFITM1 and IFITM2. American Journal of Respiratory and Critical Care Medicine 195:A2804, 2017. e-Pub 2017.
Kulkarni VV, Wang Y, Pantaleon-Garcia J, Leiva MM, Evans SE. Activation of lung epithelial NFkB and STAT3 signaling pathways is required for inducible resistance to pseudomonas infection. American Journal of Respiratory and Critical Care Medicine 195:A4036, 2017. e-Pub 2017.
Kulkarni VV, Wang Y, Pantaleon-Garcia J, Leiva MM, Wali S, Evans SE. Myddosome-activated epithelial TRAF6 is required for synergistic TLR-induced resistance to pneumonia. American Journal of Respiratory and Critical Care Medicine 195:A4035, 2017. e-Pub 2017.
Castro S, Daliri S, De La Garza MM, Cumpian AM, Umer M, Del Bosque D, Akbani S, Evans SE, Moghaddam SJ. A promoting role for the epithelial MyD88/IRAK4/NF-kB signaling in K-ras mutant lung tumorigenesis. Cancer Research 77:2679, 2017. e-Pub 2017.
Caetano MS, Van H, Bugarin E, Cumpian A, McDowell CL, Zhang H, Evans SE, Watowich S, Kadara H, Moghaddam SJ. Gender specific function of epithelial IL-6-STAT3 pathway in K-ras mutant lung cancer. Cancer Research 77:3974, 2017. e-Pub 2017.
Ware HH, Leiva-Juarez MM, Kirkpatrick CT, Wang Y, Evans SE. Treatment with synergistic TLR ligands that protect against leukemia-associated pneumonias does not worsen tumor burden. American Journal of Respiratory and Critical Care Medicine 193:A5459, 2016. e-Pub 2016.
Leiva-Juarez MM, Ware HH, Kulkarni VV, Kirkpatrick CT, Wang Y, Evans SE. Synergistic Toll-like receptor signaling-induced resistance protects mice against pneumonia in the presence of acute leukemia and cytotoxic chemotherapy. American Journal of Respiratory and Critical Care Medicine 193:A4454, 2016. e-Pub 2016.
Plumer AK, Kirkpatrick CT, Leiva-Juarez MM, Ware HH, Kulkarni VV, Wang Y, Pantaleon J, Evans SE. Mitochondrial reactive oxygen species-dependent inducible antiviral resistance in primary lung epithelial cells. American Journal of Respiratory and Critical Care Medicine 193:A5470, 2016. e-Pub 2016.
Kirkpatrick CT, Wang Y, Kulkarni VV, Plumer AK, Evans SE. Lung epithelial cell mitochondrial reactive oxygen species are required for antiviral resistance induced by synergistic Toll-like receptor signaling. American Journal of Respiratory and Critical Care Medicine 193:A4456, 2016. e-Pub 2016.
Kulkarni VV, Wang Y, Kirkpatrick CT, Leiva-Juarez MM, Plumer AK, Evans SE. Cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING) and interferon activated gene 16 (IFI16) are essential for intrinsic lung epithelial responses against influenza A infection, but not for therapeutically induced antiviral resistance. American Journal of Respiratory and Critical Care Medicine 193:A5469, 2016. e-Pub 2016.
Leiva-Juarez MM, Wu J, Kirkpatrick CT, Kulkarni V, Pantaleon-Garcia J, Martinez-Zayas G, Ware HH, Plumer AK, Zweidler-McKay PA, Evans SE. Inducible epithelial resistance protects mice against pneumonia in the presence of acute leukemia and cytotoxic chemotherapy. American Journal of Respiratory and Critical Care Medicine 191:A1028, 2015. e-Pub 2015.
Kirkpatrick CT, Pantaleon-Garcia J, Kulkarni V, Leiva-Juarez MM, Plumer AK, Evans SE. Lung epithelial cells are necessary and sufficient mediators of inducible antiviral resistance. American Journal of Respiratory and Critical Care Medicine 191:A3787, 2015. e-Pub 2015.
Pantaleon-Garcia J, Kirkpatrick CT, Kulkarni V, Martinez-Zayas G, Plumer AK, Leiva-Juarez MM, Evans SE. Inducible antiviral resistance enhances lung epithelial cell survival without modulating programmed cell death pathways. American Journal of Respiratory and Critical Care Medicine 191:A3238, 2015. e-Pub 2015.
Leiva-Juarez MM, Plumer AK, Kulkarni V, Pantaleon-Garcia J, Martinez-Zayas G, Ware HH, Evans SE. Pneumonia prophylaxis by TLR 2/6 and TLR9 stimulation is associated with an early increase in transepithelial electrical resistance independent of PKCζ activation and a late increase in macromolecular transport in bronchial epithelial cells. American Journal of Respiratory and Critical Care Medicine 191:A3236, 2015. e-Pub 2015.
Plumer AK, Leiva-Juarez MM, Kirkpatrick CT, Kulkarni V, Evans SE. Inducible resistance to viral infection in primary lung epithelial cells. American Journal of Respiratory and Critical Care Medicine 191:A3237, 2015. e-Pub 2015.
Wu J, Cleaver JO, Guzman FA, Kirkpatrick CT, Tuvim MJ, Evans SE. Inducible resistance to pneumonia requires extracanonical TLR signaling in the lung epithelium. American Journal of Respiratory and Critical Care Medicine 189:A3948, 2014. e-Pub 2014.
Kirkpatrick CT, Pantaleon J, Guzman FA, McGrath D, Michaud D, Rice A, Wu J, Cleaver JO, Evans SE. Lung epithelial cells are principle effector cells of inducible antiviral resistance. American Journal of Respiratory and Critical Care Medicine 189:A5229, 2014. e-Pub 2014.
Guzman FA, Michaud DR, Cleaver JO, Evans SE. Synergistic inducible resistance againt influenza pneumonia requires canonical TLR signaling in the lung epithelium. American Journal of Respiratory and Critical Care Medicine 187:A5261, 2013. e-Pub 2013.
Cleaver JO, Michaud DR, Guzman FA, Evans SE. Canonical TLR signaling is required, but cannot fully explain synergistic inducible resistance to bacterial pneumonia. American Journal of Respiratory and Critical Care Medicine 187:A5260, 2013. e-Pub 2013.
Evans CM, Roy M, McElwee ML, Boerner R, Mdoe VN, Cleaver JO, Moghaddam SJ, Evans SE. Critical role for Muc5b in innate immune defense in vivo. American Journal of Respiratory and Critical Care Medicine 185:A5105, 2012. e-Pub 2012.
Cleaver JO, You D, Duggan J, Evans SE. Lung epithelial TLR signaling is essential to inducible resistance to pneumonia. American Journal of Respiratory and Critical Care Medicine 185:A3272, 2012. e-Pub 2012.
Ghosh S, Rice DC, Plana JC, Fu S, Evans SE. Endocardial metastasis of cervical carcinoma manifesting as dyspnea. American Journal of Respiratory and Critical Care Medicine 181:A1902, 2010. e-Pub 2010.
Duggan JM, You D, Garza RJ, Larson DT, Tuvim MJ, Dickey BF, Evans SE. Broad resistance against pneumonia induced by synergistic TLR2/6 and TLR9 stimulation. American Journal of Respiratory and Critical Care Medicine 181:A1799, 2010. e-Pub 2010.
You D, Gilbert BE, Duggan JM, Tuvim MJ, Dickey BF, Evans SE. Induced resistance to influenza A infection by cooperative TLR2/6 and TLR9 activation. American Journal of Respiratory and Critical Care Medicine 181:A2629, 2010. e-Pub 2010.
Larson DT, Gendron C, Hook M, Dickey BF, Evans SE. Stimulated innate resistance in vitro: bacterial killing by respiratory epithelial cells. American Journal of Respiratory and Critical Care Medicine 179:A1020, 2009. e-Pub 2009.
Duggan JM, Tuvim MJ, Dickey BF, Evans SE. Toll-like receptor synergy in stimulated innate resistance. American Journal of Respiratory and Critical Care Medicine 179:A1025, 2009. e-Pub 2009.
Tuvim MJ, Evans SE, Scott B, Hook M, Dickey BF. New infectious pneumonia drugs – stimulators of innate resistance. Proceedings of Biopharma International Symposium 36, 2009. e-Pub 2009.
Evans SE, Clement CG, Scott B, Tuvim MJ, Dickey BF. Stimulation of lung innate immunity protects broadly against bacterial, fungal and viral pneumonia. American Journal of Respiratory and Critical Care Medicine 177:A433, 2008. e-Pub 2008.
Clement CG, Evans SE, Tuvim MJ, Evans CM, Dickey BF. Stimulus-specific protective and non-protective inflammatory responses in the lung. American Journal of Respiratory and Critical Care Medicine 177:A432, 2008. e-Pub 2008.
Evans SE. Interrogation of host gene expression predicts infecting respiratory pathogens. Proceedings of the American Thoracic Society 4(3):A422, 2007. e-Pub 2007.
Evans SE, Ammar KA, Rodeheffer RJ, Scanlon PD. Anthropometry & spirometry: Effects of obesity on respiratory function. Preceedings of the American Thoracic Society 1(2):A866, 2005. e-Pub 2005.
Evans SE, Kottom TJ, Limper AH. Alveolar epithelial cell caveolar function is required for Pneumocystis carinii β-glucan-induced inflammatory cytokine expression. Proceedings of the American Thoracic Society 1(2):A848, 2005. e-Pub 2005.
Evans SE, Hahn PY, Kottom TJ, Limper AH. Alveolar epithelial cell inflammatory responses to Pneumocystis carinii β-glucans require lactosylceramide, but not Dectin-1. American Journal of Respiratory and Critical Care Medicine 169:A887, 2004. e-Pub 2004.
Evans SE, Hahn PY, Kottom TJ, Limper AH. Pneumocystis carinii β-glucan induced flammatory signaling is kinase C-dependent. Chest 126(4):917S, 2004. e-Pub 2004.
Evans SE, Hahn PY, Lebron-Ruiz FM, Kottom TJ, Puri V, Pagano RE, Limper AH. Pneumocystis carinii β-glucan-induced chemokine secretion from alveolar epithelial cells requires activation of protein kinase C and NF-ĸB. Chest 124(4):188S, 2003. e-Pub 2003.
Evans SE, Hahn PY, Lebron-Ruiz FM, Puri V, Pagano RE, Limper AH. Nuclear translocation of NF-κB is required for Pneumocystis carinii β-glucan-induced chemokine production from alveolar epithelial cells. FASEB Journal 17(5):A830-1, 2003. e-Pub 2003.
Evans SE, Mottram CD, McGregor CGA, Dunn WF. Characterization of cardiopulmonary exercise testing in surgically-proven chronic thromboembolic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 167(7), 2003. e-Pub 2003.
Evans SE, Hahn PY, Lebron-Ruiz FM, Puri V, Pagano RE, LimperAH. Lactosylceramide-dependent internalization of Pneumocystis carinii β-glucan stimulates inflammatory cytokine responses from alveolar epithelial cells. American Journal of Respiratory and Critical Care Medicine 167(7):A390, 2003. e-Pub 2003.
Limper AH, Lebron FM, Evans SE, Hahn PY. Pneumocystis carinii: cell wall β-glucan-mediated pulmonary inflammation. Journal of Eukaryotic Microbiology 50(Suppl 646):646, 2003. e-Pub 2003.
Evans SE, Mottram CD, McGregor CGA, Dunn WF. Cardiopulmonary exercise testing: a potential role in the diagnosis of chronic thromboembolic pulmonary hypertension. Journal of Investigative Medicine 51(Suppl 2):S360-361, 2003. e-Pub 2003.
Evans S. Smut lung: an atypical hypersensitivity pneumonitis. Chest 124(4):279S, 2002. e-Pub 2002.
Evans SE, Colby TV, Limper AH. Cyclin dependent kinase inhibitor p27kip1 expression in non small cell lung carcinoma. Journal of Investigative Medicine 50(2):164A, 2002. e-Pub 2002.
Evans SE, Colby TV, Limper AH. Reduced expression of the cyclin dependent kinase inhibitor p27kip1 in non small cell lung carcinoma. American Journal of Respiratory and Critical Care Medicine 163(5):A476, 2001. e-Pub 2001.
Evans SE, Ryu JH, Limper AH. Transforming growth factor β1 and extracellular matrix-associated fibronectin expression in lymphangioleiomyomatosis. Chest 120(4):208S, 2001. e-Pub 2001.

Book Chapters

Evans SE, Staitieh BS, Hohl T. Innate and Acquired Immunity. In: Murray & Nadel’s Textbook of Respiratory Medicine. 8. Elsevier, 2026.
Ashley, DM, Evans, S. Bacterial Pneumonia in Hematopoietic Stem Cell Transplant Recipients, 107-118, 2023.
Ashley DM, Evans SE. Bacterial Pneumonia in Hematopeoiteic Stem Cell Transplant Recipients. In: Pulmonary and Critical Care Considerations of Hematopoietic Stem Cell Transplantation. Springer Nature, 2023.
Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Vazquez WR, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors- Related Pulmonary Complications. In: Immune Cell Lineage Reprogramming in Cancer. Frontiers, 40-49, 2022.
Sagar, AS, Evans, S. Pneumonia in the cancer patient, 607-623, 2019.
Sagar AES, Evans SE. Pneumonia in the Cancer Patient. In: Oncologic Critical Care. Springer Nature, 2019.
Evans SE, Safdar A. Pneumonia in the Critically Ill Cancer Patient. In: Cancer Critical Care. Springer Science + Business Media, 2018.
Shannon VR, Eapen GA, Jimenez CA, Grosu HB, Morice RC, Bashoura L, Evans SE, Adachi R, Kroll M, Faiz SA, Balachandran DD, Pravinkumar SE, Dickey BF. Respiratory Complications. In: Holland-Frei Cancer Medicine. 9. John Wiley and Sons, Inc, 1781-1805, 2017.
Evans SE, Safdar A. Pneumonia and Other Lung Infections. In: Principles and Practice of Cancer Infectious Diseases. Humana Press, 2011.
Shannon VR, Evans SE, et al. Respiratory Complications. In: Holland-Frei Cancer Medicine. 8. BC Decker, 2010.
Evans, S, Scanlon, PD, Culver, BH. Pulmonary function testing, 147-155, 2008.
Evans SE, Scanlon PD, Culver BH. Pulmonary Function Testing. In: Comprehensive Respiratory Medicine, 3rd Edition. 3. Elsevier, 147-155, 2008.
Evans, S, Limper, AH. Acute toxicities of therapy, 1410-1419, 2006.
Evans SE, Limper AH. Chemotherapy-Induced Lung Disease - An Evidence-Based Approach. In: Oncology: An Evidence-Based Approach. Springer-Verlag, 1401-1410, 2005.
Evans SE, Limper AH. HIV: North American Perspective. In: Tropical and Parasitic Infections in the ICU. Kluwer Academic Publishers, 127-144, 2004.

Letters to the Editor

Pantaleón García J, Hinkle KJ, Falkowski NR, Evans SE, Dickson RP. Response to "Response of Lung Microbiota to Changes of Pulmonary Innate Immunity Under Healthy Conditions". Am J Respir Crit Care Med 205: 477-479, 2022.
Ramirez JA, Musher DM, Evans SE. Response. Chest 158: 2703-2704, 2020.

Patents

Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 8883174.
Hook M, Zhang D, Gendron C, Dickey BF, Tuvim MJ, Evans SE. Methods and Compositions for Stimulation of Mammalian Innate Immune System Resistance to Pathogens. Patent Number: PCT/US2009/05652.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: PI1009842.9.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 10716433.7.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: ZL 201310588997.2.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 10-1856462.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 16105189.2.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 10722573.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 10-1730351.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Methods and Compositions for Adaptive Immune Modulation. Patent Number: 2017356673.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogen. Patent Number: 8883174.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2756412.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Methods and Compositions for Adaptive Immune Modulation. Patent Number: 3043480.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: J/002843.
Bickey DF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 10716433.7.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: J/4279.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 323304.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 9186400.
Dickey BF, Tuvim MJ, Evans SE. Methods and Compositions for Adaptive Immune Modulation. Patent Number: P6000670/2019.
Dickey BF, Tuvim MJ, Evans SE. Methods and Compositions for Adaptive Immune Modulation. Patent Number: 2020/06745.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: ZL 201080022634.7.
Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 215288.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Methods and Compositions for Adaptive Immune Modulation. Patent Number: BR112019009469-5.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: J/001878.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 309121.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: ZL 201510337464.6.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 240202.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2015201861.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: P935/11.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2411521.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 16/937967.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2011/07774.
Dickey BF, Evans SE, Gilbert BE, Markesich D, Scott BD, Tuvim MJ. Compositions and Methods for Treating Viral Infections Through Stimulated Innate Immunity in Combination with Antiviral Compounds. Patent Number: 10286065.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 2010229835.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 6084655.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 5759445.
Dickey BF, Tuvim MJ, Evans SE. Compositions for Stimulation of Mammalian Innate Immune Resistance to Pathogens. Patent Number: 9504742.

Less

Selected Presentations & Talks

Local Presentations

2023. Inducible epithelial resistance to prevent acute and chronic lung disease. Inducible epithelial resistance to prevent acute and chronic lung disease. Houston, TX, US.
2021. Novel cooperation between RelA and c-Jun promotes differential NF-kB activation required for inducible epithelial resistance against viral pneumonia. Novel cooperation between RelA and c-Jun promotes differential NF-kB activation required for inducible epithelial resistance against viral pneumonia. Houston, TX, US.
2020. Inducible resistance against COVID-19. Inducible resistance against COVID-19. Houston, TX, US.
2019. Inducible epithelial resistance to prevent acute and chronic complications of pneumonia. Inducible epithelial resistance to prevent acute and chronic complications of pneumonia. Houston, TX, US.
2019. Inducible resistance to prevent pneumonia in patients with hematologic malignancies. Inducible resistance to prevent pneumonia in patients with hematologic malignancies. Houston, TX, US.
2016. Inducible epithelial resistance to prevent viral pneumonia. Inducible epithelial resistance to prevent viral pneumonia. Houston, TX, US.
2015. Prevention of pneumonia in cancer patients with TLR ligands. Prevention of pneumonia in cancer patients with TLR ligands. Houston, TX, US.
2013. Leukemia-associated pneumonia: incidence, impact and novel prevention strategies. Leukemia-associated pneumonia: incidence, impact and novel prevention strategies. Houston, TX, US.
2012. Inducible Resistance to Pneumonia. Inducible Resistance to Pneumonia. Houston, TX, US.
2012. Inducible resistance to prevent leukemia-associated pneumonia. Inducible resistance to prevent leukemia-associated pneumonia. Houston, TX, US.
2011. Toll-like receptor-induced epithelial resistance to pneumonia. Toll-like receptor-induced epithelial resistance to pneumonia. Houston, TX, US.
2010. Stimulated innate resistance against pneumonia in patients with leukemia. Stimulated innate resistance against pneumonia in patients with leukemia. Houston, TX, US.
2009. Toll-like receptor synergy in stimulated innate resistance. Toll-like receptor synergy in stimulated innate resistance. Houston, TX, US.
2009. Stimulated innate resistance in vitro:bacterial killing by respiratory epithelial cells. Stimulated innate resistance in vitro:bacterial killing by respiratory epithelial cells. Houston, TX, US.
2007. Host gene expression profiles distinguished between infecting pathogens in an experimental model of murine pneumonia. Host gene expression profiles distinguished between infecting pathogens in an experimental model of murine pneumonia. Houston, TX, US.
2007. Compliance and documentation pneumonia performance indicators in the MDACC Emergency Center. Compliance and documentation pneumonia performance indicators in the MDACC Emergency Center. Houston, TX, US.
2007. Compliance and documentation of established pneumonial indicators in the MDACC Emergency Center. Compliance and documentation of established pneumonial indicators in the MDACC Emergency Center. Houston, TX, US.

Regional Presentations

2001. Renal disease in primary systemic amyloidosis. Conference. Renal disease in primary systemic amyloidosis. Rochester, MN, US.
1999. A 26 year-old Somali female with tuberculosis and multiple tropical infections. Conference. A 26 year-old Somali female with tuberculosis and multiple tropical infections. Minneapolis, MN, US.
1999. Respiratory isolation in smear-negative tuberculosis. Conference. Respiratory isolation in smear-negative tuberculosis. Rochester, MN, US.
1998. Prospective randomized controlled study of the effects of glucocorticoid dosing on acute and chronic rejection of lung allografts. Conference. Prospective randomized controlled study of the effects of glucocorticoid dosing on acute and chronic rejection of lung allografts. Dallas, TX, US.
1998. Rhodococcus equi pneumonia presenting as spontaneous pneumothorax. Conference. Rhodococcus equi pneumonia presenting as spontaneous pneumothorax. San Antonio, TX, US.
1998. Basics of resident and student community involvement. Conference. Basics of resident and student community involvement. Austin, TX, US.

International Presentations

2025. Approach to the management of pulmonary infections in immunocompromised patients. Invited. 3rd World Symposium in Oncologic Critical Care, US.
2025. Stimulating Lung Innate Immunity to Prevent Respiratory Infection. Invited. American Thoracic Society International Conference. San Francisco, US.
2025. Therapeutic Hypoxia-Inducible Factor 1a Stabilization Activates Antimicrobial Peptide Expression and Prevents Bacterial Pneumonia. Conference. American Thoracic Society International Conference. San Francisco, US.
2025. Inhalation of synergistic pattern recognition receptor agonists activates an IRF9-dependent DUOX2 antiviral immune response to protect against influenza virus infection. Conference. American Thoracic Society International Conference. San Francisco, US.
2025. Epithelial immunomodulation by aerosolized Toll-like receptor agonists prevents allergic lung inflammation by reducing Th2 polarization. Conference. American Thoracic Society International Conference. San Francisco, US.
2025. Stimulating innate immunity to prevent pneumonia. Conference. American Thoracic Society International Conference. San Francisco, US.
2025. Multifunctional roles of oligodeoxynucleotides in inducible epithelial resistance against pneumonia. Invited. International Respiratory Infections Society Conference, US.
2024. Immunometabolic reprogramming of lung epithelial cells to protect against pneumonia. Invited. Immunometabolic reprogramming of lung epithelial cells to protect against pneumonia. San Diego, US.
2023. Strengthening the armamentarium against respiratory infections. Invited. Strengthening the armamentarium against respiratory infections. Manilla, PH.
2023. The new challenges of immunocompromised host pneumonia. Invited. The new challenges of immunocompromised host pneumonia. Milan, IT.
2023. Antimicrobial mitochondrial reactive oxygen species induction by lung epithelial metabolic reprogramming. Conference. Antimicrobial mitochondrial reactive oxygen species induction by lung epithelial metabolic reprogramming. Milan, IT.
2023. Therapeutic manipulation of lung epithelial immune responses to prevent and treat pneumonia. Conference. Therapeutic manipulation of lung epithelial immune responses to prevent and treat pneumonia. Lausanne (Virtual), CH.
2023. Modeling inducible epithelial resistance against murine betacoronavirus. Conference. Modeling inducible epithelial resistance against murine betacoronavirus. Washington, US.
2023. RIG-I is a cytosolic receptor of CPG oligodeoxynucleotides that can be manipulated to protect against pneumonia. Conference. RIG-I is a cytosolic receptor of CPG oligodeoxynucleotides that can be manipulated to protect against pneumonia. Washinton, US.
2023. Antiviral mitochondrial reactive oxygen species induction by lung epithelial metabolic reprogramming. Invited. Antiviral mitochondrial reactive oxygen species induction by lung epithelial metabolic reprogramming. Snowbird, US.
2023. Chronic pulmonary complications of community-acquired pneumonia. Conference. American Thoracic Society 2023 International Conference. New York (Virtual), US.
2022. Stimulating lung innate immunity to prevent respiratory infection. Conference. Stimulating lung innate immunity to prevent respiratory infection. San Francisco, US.
2022. Collateral Damage: Pneumonia in the setting of immunosuppressive medications. Invited. Collateral Damage: Pneumonia in the setting of immunosuppressive medications. San Francisco, US.
2022. Fundamentals of Writing Successful Research Project Grants: Mock study secton for R01 grant review. Invited. Fundamentals of Writing Successful Research Project Grants: Mock study secton for R01 grant review. San Francisco, US.
2022. Recent ATS Clinical Practice Guidelines: Community acquired pneumonia PCR testing. Conference. Recent ATS Clinical Practice Guidelines: Community acquired pneumonia PCR testing. San Francisco, US.
2021. Transcriptional cooperation between RelA and Jun/Fos promotes differential NF-kB activity required for inducible epithelial resistance against viral pneumonia. Conference. Transcriptional cooperation between RelA and Jun/Fos promotes differential NF-kB activity required for inducible epithelial resistance against viral pneumonia. San Diego (Virtual), US.
2021. ATS Fungal Diagnosis Guidelines: what’s in there about aspergillosis?. Conference. ATS Fungal Diagnosis Guidelines: what’s in there about aspergillosis?. San Diego (virtual), US.
2021. Pneumonia in patients with hematologic malignancies. Invited. Pneumonia in patients with hematologic malignancies. Orlando (Virtual), US.
2020. Phosphorothiorate oligodeoxynucleotide-induced antimicrobial epithelial mitochondrial reactive oxygen species protect against pneumonia. Conference. Phosphorothiorate oligodeoxynucleotide-induced antimicrobial epithelial mitochondrial reactive oxygen species protect against pneumonia. Vienna (Virtual), AT.
2020. Aerosolized TLR agonists suppress sensitization to house dust mite in mice. Conference. Aerosolized TLR agonists suppress sensitization to house dust mite in mice. Philadelphia, US.
2020. Inducible epithelial resistance inactivates sendai virus and protects against CD8+ T cell mediated immunopathology. Conference. Inducible epithelial resistance inactivates sendai virus and protects against CD8+ T cell mediated immunopathology. Philadelphia (Virtual), US.
2020. Harvesting innate immune function to protect patients against pneumonia. Invited. Harvesting innate immune function to protect patients against pneumonia. Philadelphia (Virtual), US.
2019. Scientific update in inducible epithelial resistance. Invited. Scientific update in inducible epithelial resistance. Dallas, US.
2019. Synergistic gene and protein expression analyses reveal roles of NFkB and JUN in inducible epiethlial resistance. Conference. Synergistic gene and protein expression analyses reveal roles of NFkB and JUN in inducible epiethlial resistance. Dallas, US.
2019. Inducible resistance to prevent pneumonia in patients with hematologic malignancies. Invited. Inducible resistance to prevent pneumonia in patients with hematologic malignancies. Houston, US.
2019. Postgraduate Course: Harnessing innate immunity to protect against pneumonia. Invited. Postgraduate Course: Harnessing innate immunity to protect against pneumonia. Dallas, US.
2018. Inducible Epithelial Resistance to Pneumonia. Conference. Inducible Epithelial Resistance to Pneumonia. Ventura, US.
2018. Pneumonia in patients with hematologic malignancies and HSCT recipients. Invited. Pneumonia in patients with hematologic malignancies and HSCT recipients. San Diego, US.
2018. Host risk factors & susceptibilities to pneumonia. Invited. Host risk factors & susceptibilities to pneumonia. San Diego, US.
2018. Keynote Address, Bernard Harris Medical Society Meeting: Precision Medicine. Invited. Keynote Address, Bernard Harris Medical Society Meeting: Precision Medicine. Lubbock, US.
2017. Myddosome-activated epithelial TRAF6 is required for synergistic TLR-induced resistance to pneumonia. Conference. Myddosome-activated epithelial TRAF6 is required for synergistic TLR-induced resistance to pneumonia. Washington, US.
2017. Protection against viral pneumonia following inhalation of synergistic TLR agonists is not mediated by induction of type I interferons. Conference. Protection against viral pneumonia following inhalation of synergistic TLR agonists is not mediated by induction of type I interferons. Washington, US.
2017. Progression of radiologic infiltrates after parainfluenza infection predicts mortality in patients with hematologic malignancies. Conference. Progression of radiologic infiltrates after parainfluenza infection predicts mortality in patients with hematologic malignancies. Washington, US.
2017. Mitochondrial reactive oxygen species in lung epithelial cells are induced by oligodeoxynucleotides in a MyD88 and TRAF6-independent matter. Conference. Mitochondrial reactive oxygen species in lung epithelial cells are induced by oligodeoxynucleotides in a MyD88 and TRAF6-independent matter. Washington, US.
2017. Activation of lung epithelial NFkB and STAT3 signaling pathways is required for inducible resistance to pseudomonas infection. Conference. Activation of lung epithelial NFkB and STAT3 signaling pathways is required for inducible resistance to pseudomonas infection. Washington, US.
2017. Pneumonia in Hematologic Malignancies, Chemotherapy and Blood Disorder. Invited. Pneumonia in Hematologic Malignancies, Chemotherapy and Blood Disorder. Bethesda, US.
2017. Pneumonia during cancer chemotherapy or stem cell transplantation. Invited. Pneumonia during cancer chemotherapy or stem cell transplantation. Washington, US.
2016. Current therapeutic approaches for fungal pneumonia. Invited. Current therapeutic approaches for fungal pneumonia. San Francisco, US.
2016. Cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING) and interferon activated gene 16 (IFI16) are essential for intrinsic lung epithelial responses against influenza A infection, but not for therapeutically induced antiviral resistance. Conference. Cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING) and interferon activated gene 16 (IFI16) are essential for intrinsic lung epithelial responses against influenza A infection, but not for therapeutically induced antiviral resistance. San Francisco, US.
2016. Treatment with synergistic TLR ligands that protect against leukemia-associated pneumonias does not worsen tumor burden. Conference. Treatment with synergistic TLR ligands that protect against leukemia-associated pneumonias does not worsen tumor burden. San Francisco, US.
2016. Synergistic Toll-like receptor signaling-induced resistance protects mice against pneumonia in the presence of acute leukemia and cytotoxic chemotherapy. Conference. Synergistic Toll-like receptor signaling-induced resistance protects mice against pneumonia in the presence of acute leukemia and cytotoxic chemotherapy. San Francisco, US.
2016. Synergistic TLR signaling in the lung epithelium induces mitochondrial ROS dependent antiviral resistance. Conference. Synergistic TLR signaling in the lung epithelium induces mitochondrial ROS dependent antiviral resistance. Galveston, US.
2016. Lung epithelial cell mitochondrial reactive oxygen species are required for antiviral resistance induced by synergistic Toll-like receptor signaling. Conference. Lung epithelial cell mitochondrial reactive oxygen species are required for antiviral resistance induced by synergistic Toll-like receptor signaling. San Francisco, US.
2016. Pneumonia in patients with hematologic malignancies and HSCT recipients. Invited. Pneumonia in patients with hematologic malignancies and HSCT recipients. San Francisco, US.
2015. Pneumonia prophylaxis by TLR 2/6 and TLR9 stimulation is associated with an early increase in transepithelial electrical resistance independent of PKCζ activation and a late increase in macromolecular transport in bronchial epithelial cells. Conference. Pneumonia prophylaxis by TLR 2/6 and TLR9 stimulation is associated with an early increase in transepithelial electrical resistance independent of PKCζ activation and a late increase in macromolecular transport in bronchial epithelial cells. Denver, US.
2015. Inducible epithelial resistance protects mice against pneumonia in the presence of acute leukemia and cytotoxic chemotherapy. Conference. Inducible epithelial resistance protects mice against pneumonia in the presence of acute leukemia and cytotoxic chemotherapy. Denver, US.
2015. Inducible resistance to viral infection in primary lung epithelial cells. Conference. Inducible resistance to viral infection in primary lung epithelial cells. Denver, US.
2015. Inducible antiviral resistance enhances lung epithelial cell survival without modulating programmed cell death pathways. Conference. Inducible antiviral resistance enhances lung epithelial cell survival without modulating programmed cell death pathways. Denver, US.
2015. Lung epithelial cells are necessary and sufficient mediators of inducible antiviral resistance. Conference. Lung epithelial cells are necessary and sufficient mediators of inducible antiviral resistance. Denver, US.
2015. Lung epithelial cells are principal effectors of inducible antiviral resistance. Conference. Lung epithelial cells are principal effectors of inducible antiviral resistance. Breckenridge, US.
2015. Synergistic Toll-like receptor-induced resistance protects mice against pneumonia in the presence of acute leukemia and cytotoxic chemotherapy. Conference. Synergistic Toll-like receptor-induced resistance protects mice against pneumonia in the presence of acute leukemia and cytotoxic chemotherapy. Marbella, ES.
2015. Synergistic Toll-like receptor signaling in lung epithelial cells induces mitochondrial reactive species-dependent antiviral resistance. Conference. Synergistic Toll-like receptor signaling in lung epithelial cells induces mitochondrial reactive species-dependent antiviral resistance. Marbella, ES.
2014. Lung epithelial cells are principal effectors of inducible antiviral resistance. Conference. Lung epithelial cells are principal effectors of inducible antiviral resistance. San Diego, US.
2014. Inducible epithelial resistance requires extracanonical TLR signaling. Conference. Inducible epithelial resistance requires extracanonical TLR signaling. San Diego, US.
2014. Inducible epithelial resistance to pneumonia requires extracanonical TLR signaling. Conference. Inducible epithelial resistance to pneumonia requires extracanonical TLR signaling. Lucca, IT.
2013. Canonical TLR signaling is required, but cannot fully explain synergistic inducible resistance to pneumonia. Conference. Canonical TLR signaling is required, but cannot fully explain synergistic inducible resistance to pneumonia. Philadelphia, US.
2013. Inducible epithelial resistance to prevent pneumonia. Invited. Inducible epithelial resistance to prevent pneumonia. Nashville, US.
2013. In vitro testing for synergistic inducible resistance against influenza A pneumonia in lung epithelial cells. Conference. In vitro testing for synergistic inducible resistance against influenza A pneumonia in lung epithelial cells. Mexico City, MX.
2013. Pneumonia in the cancer patient on chemotherapy. Invited. Pneumonia in the cancer patient on chemotherapy. Philadelphia, US.
2013. Synergistic inducible resistance to pneumonia requires canonical signaling in the lung epithelium. Conference. Synergistic inducible resistance to pneumonia requires canonical signaling in the lung epithelium. Philadelphia, US.
2012. Compliance with established pneumonia core measures at MD Anderson Cancer Center in the Emergency Center. Conference. Compliance with established pneumonia core measures at MD Anderson Cancer Center in the Emergency Center. San Diego, US.
2011. Quality care in cancer patients with pneumonia. Conference. Quality care in cancer patients with pneumonia. Orlando, US.
2011. Lung epithelial cells are important effectors of inducible resistance to pneumonia. Conference. Lung epithelial cells are important effectors of inducible resistance to pneumonia. Denver, US.
2011. New concepts in host defense: epithelial cells in lung defense. Invited. New concepts in host defense: epithelial cells in lung defense. Denver, US.
2011. Epithelial resistance to pneumonia induced by TLR synergy. Conference. Epithelial resistance to pneumonia induced by TLR synergy. Vancouver, CA.
2010. Induced resistance to influenza A infection by cooperative TLR2/6 and TLR9 activation. Conference. Induced resistance to influenza A infection by cooperative TLR2/6 and TLR9 activation. New Orleans, US.
2010. Broad resistance against pneumonia induced by synergistic TLR2/6 and TLR9 stimulation. Conference. Broad resistance against pneumonia induced by synergistic TLR2/6 and TLR9 stimulation. New Orleans, US.
2010. Synergistic interactions of TLR2/6 and TLR9 induce a high level of epithelial resistance to lung infection. Conference. Synergistic interactions of TLR2/6 and TLR9 induce a high level of epithelial resistance to lung infection. Ventura, US.
2009. Stimulated innate resistance in vitro: bacterial killing by respiratory epithelial cells. Conference. Stimulated innate resistance in vitro: bacterial killing by respiratory epithelial cells. San Diego, US.
2009. Stimulated innate resistance from the lung epithelium. Invited. Stimulated innate resistance from the lung epithelium. Ventura, US.
2009. Compliance & documentation with established pneumonia indicators in MDACC emergency center. Conference. Compliance & documentation with established pneumonia indicators in MDACC emergency center. Berlin, DE.
2009. Toll-like receptor synergy in stimulated innate resistance. Conference. Toll-like receptor synergy in stimulated innate resistance. San Diego, US.
2008. Pneumonia in patients with cancer. Invited. Pneumonia in patients with cancer. Barcelona, ES.
2008. Stimulation of lung innate immunity protects mice broadly against bacterial, fungal and viral pneumonia. Conference. Stimulation of lung innate immunity protects mice broadly against bacterial, fungal and viral pneumonia. Ventura, US.
2008. Stimulus-specific protective and non-protective inflammatory responses in the airways. Conference. Stimulus-specific protective and non-protective inflammatory responses in the airways. Toronto, CA.
2008. Stimulation of lung innate immunity protects mice broadly against bacterial, fungal and viral pneumonia. Conference. Stimulation of lung innate immunity protects mice broadly against bacterial, fungal and viral pneumonia. Toronto, CA.
2008. Stimulation of lung innate immunity protects mice broadly against bacterial, fungal and viral pneumonia. Conference. Stimulation of lung innate immunity protects mice broadly against bacterial, fungal and viral pneumonia. Chania, GR.
2007. Interrogation of host gene expression predicts infecting respiratory pathogens. Conference. Interrogation of host gene expression predicts infecting respiratory pathogens. San Francisco, US.
2005. Alveolar epithelial cell caveolar function is required for Pneumocystis carinii β-glucan-induced inflammatory cytokine production. Conference. Alveolar epithelial cell caveolar function is required for Pneumocystis carinii β-glucan-induced inflammatory cytokine production. San Diego, US.
2005. Anthropometry & Spirometry: effects of obesity on respiratory function. Conference. Anthropometry & Spirometry: effects of obesity on respiratory function. San Diego, US.
2004. Pneumocystis carinii β-glucan. Conference. Pneumocystis carinii β-glucan. Seattle, US.
2004. Alveolar epithelial inflammatory responses to Pneumocystic carinii β-glucan are dependent on lactosylceramide, but not Dectin-1. Conference. Alveolar epithelial inflammatory responses to Pneumocystic carinii β-glucan are dependent on lactosylceramide, but not Dectin-1. Orlando, US.
2003. Pneumocystis carinii β-glucan-induced chemokine secretion from alveolar epithelial cells requires activation of protein kinase C and NF-ĸB. Conference. Pneumocystis carinii β-glucan-induced chemokine secretion from alveolar epithelial cells requires activation of protein kinase C and NF-ĸB. Orlando, US.
2003. Cardiopulmonary exercise testing: a potential role in the diagnosis of chronic thromboembolic pulmonary hypertension. Conference. Cardiopulmonary exercise testing: a potential role in the diagnosis of chronic thromboembolic pulmonary hypertension. Baltimore, US.
2003. Characterization of cardiopulmonary exercise testing in surgically-proven chronic thromboembolic pulmonary hypertension. Conference. Characterization of cardiopulmonary exercise testing in surgically-proven chronic thromboembolic pulmonary hypertension. Seattle, US.
2003. Nuclear translocation of NF-ĸB is required for Pneumocystis carinii β-glucan-induced chemokine production from alveolar epithelial cells. Conference. Nuclear translocation of NF-ĸB is required for Pneumocystis carinii β-glucan-induced chemokine production from alveolar epithelial cells. San Diego, US.
2003. Smut lung: an atypical hypersensitivity pneumonia. Conference. Smut lung: an atypical hypersensitivity pneumonia. Orlando, US.
2002. Cyclin dependent kinase inhibitor p27kip1 expression in non small cell carcinoma. Conference. Cyclin dependent kinase inhibitor p27kip1 expression in non small cell carcinoma. Baltimore, US.
2002. Expression of extracellular matrix associated transforming growth factor-β1 and fibronectin in pulmonary lymphangioleiomyomatosis. Conference. Expression of extracellular matrix associated transforming growth factor-β1 and fibronectin in pulmonary lymphangioleiomyomatosis. Chicago, US.
2002. Lactosylceramide-dependent internalization of Pneumocystis carinii β-glucan stimulates inflammatory cytokine responses from alveolar epithelial cells. Conference. Lactosylceramide-dependent internalization of Pneumocystis carinii β-glucan stimulates inflammatory cytokine responses from alveolar epithelial cells. Seattle, US.
2001. Transforming growth factor β1 and extracellular matrix associated fibronectin expression in lymphangioleiomyomatosis. Conference. Transforming growth factor β1 and extracellular matrix associated fibronectin expression in lymphangioleiomyomatosis. Philadelphia, US.
2001. Expression of transforming growth factor β1 and extracellular matrix associated fibronectin in lymphangioleiomyomatosis. Conference. Expression of transforming growth factor β1 and extracellular matrix associated fibronectin in lymphangioleiomyomatosis. Cincinnati, US.
2001. Reduced expression of the cyclin dependent kinase inhibitor p27kip1 in non small cell lung carcinoma. Conference. Reduced expression of the cyclin dependent kinase inhibitor p27kip1 in non small cell lung carcinoma. San Francisco, US.
1998. Medical student perspectives of communication instruction. Conference. Medical student perspectives of communication instruction. Phoenix, US.
1998. Development of medical student outreach programs. Conference. Development of medical student outreach programs. New Orleans, US.
1998. Draw the line: abuse in medical education. Conference. Draw the line: abuse in medical education. New Orleans, US.
1998. Funding changes in graduate medical education. Conference. Funding changes in graduate medical education. Chicago, US.

Formal Peers

2024. Inducible epithelial resistance to prevent acute and chronic lung disease. Invited. Iowa City, IA, US.
2023. My leadership journey in pulmonary medicine. Invited. Denver, CO, US.
2023. Inducible epithelial resistance to prevent acute and chronic complications of pneumonia. Invited. Worcester, MA, US.
2021. Inducible epithelial resistance to prevent pneumonia. Invited. Tucson (Virtual), AZ, US.
2021. Inducible epithelial resistance to prevent pneumonia. Visiting. New Orleans, LA, US.
2021. Inducible epithelial resistance to prevent pneumonia. Invited. Houston (virtual), TX, US.
2021. Inducible epithelial resistance to prevent pneumonia. Invited. Grand Forks (virtual), ND, US.
2019. Inducible epithelial resistance: potential to mitigate asthma and COPD exacerbations. Invited. Gaithersburg, MD, US.
2019. Inducible epithelial resistance to prevent pneumonia. Invited. New Orleans, LA, US.
2017. Inducible epithelial resistance to prevent pneumonia. Visiting. Houston, TX, US.
2016. Fungal pneumonia. Invited. Houston, TX, US.
2016. Inducible epithelial resistance to prevent pneumonia. Invited. Columbia, MO, US.
2016. Inducible epithelial resistance to prevent leukemia-associated pneumonia. Invited. Houston, TX, US.
2016. Inducible epithelial resistance to prevent AML-associated pneumonia. Invited. New York, NY, US.
2016. Inducible epithelial resistance to prevent leukemia-associated pneumonia. Invited. Ann Arbor, MI, US.
2016. Inducible epithelial resistance to prevent leukemia-associated pneumonia. Visiting. Ann Arbor, MI, US.
2015. Inducible epithelial resistance to pneumonia. Visiting. New Haven, CT, US.
2015. Inducible epithelial resistance to pneumonia. Invited. New Haven, CT, US.
2014. Inducible epithelial resistance to prevent cancer-associated pneumonia. Invited. Houston, TX, US.
2012. Inducible epithelial resistance to prevent pneumonia. Invited. Houston, TX, US.
2012. Inducible epithelial resistance to prevent pneumonia. Invited. Baton Rouge, LA, US.
2012. Inducible epithelial resistance to prevent pneumonia. Visiting. Baton Rouge, LA, US.
2011. Inducible epithelial resistance to pneumonia. Visiting. Rochester, MN, US.
2011. Epithelial resistance to pneumonia induced by TLR synergy. Invited. Portland, OR, US.
2011. Inducible epithelial resistance to pneumonia. Invited. Houston, TX, US.
2011. Inducible epithelial resistance to pneumonia. Invited. Houston, TX, US.
2011. Inducible epithelial resistance to pneumonia. Invited. Houston, TX, US.
2009. Stimulated innate resistance against pneumonia. Invited. Houston, TX, US.
2009. Inducible innate resistance from the lung epithelium. Invited. Houston, TX, US.
2008. The respiratory epithelium in pneumonia: diagnostic and protective roles. Invited. Houston, TX, US.
2008. Stimulation of lung innate immunity protects mice broadly against bacterial, fungal and viral pneumonia. Invited. Houston, TX, US.
2008. The respiratory epithelium in pneumonia: diagnostic and protective roles. Invited. Houston, TX, US.
2004. Alveolar epithelial cell inflammation in Pneumocystis carinii infection. Invited. San Antonio, TX, US.

Less

Grant & Contract Support

Date:	2026 - 2030
Title:	Hypoxia-Inducible Factors (HIFs) during Acute Respiratory Distress Syndrome
Funding Source:	NIH/NHLBI
Role:	Project Leader
ID:	1P01HL182637-01

Date:	2025 - 2032
Title:	Inducible epithelial resistance: a program investigating host-directed mechanisms of protection against infectious and allergic lung disease
Funding Source:	NIH/NHLBI
Role:	PI
ID:	R35HL183416

Date:	2025 - 2030
Title:	Immuno-protection and adjunctive therapeutic efficacy of nebulized pattern recognition receptor agonists in immunosuppressed mice with mold pneumonia
Funding Source:	NIH/NHLBI
Role:	MPI
ID:	R21AI195288

Date:	2021 - 2026
Title:	Chair ad interim retention funds
Funding Source:	University of Texas MD Anderson Cancer Center, Office of the Chief Academic Officer
Role:	PI

Date:	2019 - 2022
Title:	Synergistic induction of epithelial mitochondrial reactive oxygen species to prevent pneumonia
Funding Source:	The Cyrus Family Foundation
Role:	PI
ID:	Cyrus Scholar Award

Date:	2019 - 2026
Title:	Inducible epithelial resistance: a program investigating mechanisms to protect against acute and chronic complications of pneumonia
Funding Source:	NIH/NHLBI
Role:	PI
ID:	R35HL144805

Date:	2019 - 2023
Title:	Epithelial mechanisms of inducible resistance to AML-associated pneumonia
Funding Source:	NIH/NHLBI
Role:	PI
ID:	R01HL117976

Date:	2017 - 2021
Title:	Faculty Retention Funds
Funding Source:	University of Texas MD Anderson Cancer Center, Office of the Provost
Role:	PI

Date:	2014 - 2018
Title:	Epithelial mechanisms of inducible resistance to AML-associated pneumonia
Funding Source:	NIH/NHLBI
Role:	PI
ID:	R01 HL117976

Date:	2013 - 2016
Title:	Inducible epithelial resistance to prevent leukemia-associated pneumonia
Funding Source:	The Cyrus Family Foundation
Role:	PI
ID:	Cyrus Scholar Award

Date:	2013 - 2018
Title:	Inducible epithelial antiviral resistance to prevent asthma
Funding Source:	NIH/NHLBI
Role:	PI
ID:	DP2 HL123229

Date:	2012 - 2013
Title:	Mechanisms of inducible epithelial resistance to cancer-related pneumonia
Funding Source:	TJ Martell Foundation
Role:	PI

Date:	2012 - 2015
Title:	Expanding the market and success rates for myeloablative cancer treatments using PUL-042, an innate immune stimulant
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	CP120014

Date:	2010 - 2013
Title:	Inducible innate resistance of the lung epithelium to infection
Funding Source:	MD Anderson/NIH Cancer Center Support Grant, Multidisciplinary Research Project
Role:	Co-I
ID:	P30 CA016672

Date:	2009 - 2012
Title:	Induced resistance to influenza A infection by cooperative TLR2/6 and TLR9 signaling
Funding Source:	The Cyrus Family Foundation
Role:	PI
ID:	Cyrus Scholar Award

Date:	2009 - 2010
Title:	Mechanisms of stimulated innate resistance that protect against pneumonia among leukemia patients
Funding Source:	Leukemia Research Foundation
Role:	PI

Date:	2009 - 2011
Title:	Interrogation of host gene expression predicts the etiology of infectious pneumonia
Funding Source:	NIH Division of Loan Repayment
Role:	PI

Date:	2009 - 2014
Title:	Stimulated innate resistance of the lungs to bioterror pathogens
Funding Source:	NIH/NIAID
Role:	Project Leader
ID:	U01 AI82226

Date:	2008 - 2013
Title:	Epithelial mechanisms of inducible lung innate immunity that protect broadly against pneumonia
Funding Source:	MD Anderson Physician-Scientist Program/NIH Cancer Center Support Grant
Role:	PI
ID:	P30 CA016672

Date:	2008 - 2011
Title:	Mechanisms of inducible innate immunity that protect broadly against pneumonia
Funding Source:	Charles E. Culpeper Foundation/Partnership for Cures
Role:	PI
ID:	Culpeper Scholarship in Medical Science

Date:	2008 - 2009
Title:	Induction of the lung innate immunity that protects broadly against pneumonia during leukemia therapy
Funding Source:	MD Anderson Leukemia SPORE
Role:	PI
ID:	NIH P50 CA100632

Date:	2007 - 2009
Title:	Interrogation of host gene expression response predicts the etiology of infectious pneumonia
Funding Source:	NIH Division of Loan Repayment
Role:	PI

Date:	2007 - 2010
Title:	Interrogation of host gene expression response predicts the etiology of infections pneumonia
Funding Source:	NIH/NCRR
Role:	PI
ID:	KL2 RR024149

CV information above last modified June 30, 2025

Scott E. Evans, MD, FCCP, ATSF

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patents

Selected Presentations & Talks

Local Presentations

Regional Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Scott E. Evans, MD, FCCP, ATSF

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patents

Selected Presentations & Talks

Local Presentations

Regional Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer